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The avermectins (ivermectin, doramectin etc) and milbemycins are effective 
anthelmintics used widely in animal and human medicine for the past twenty years. 
The actual site of action of the avermectins on the GluCl is unclear, but binding 
studies have concluded that it does not share a binding site with glutamate. The 
GluCl channels have been well characterised in Caenorhabditis elegans and are 
beginning to be characterised in parasitic nematode species such as Haemonchus 
contortus, Dirofilaria immitis and Cooperia oncophora. 
The aim of this project was to characterise the H. contortus GluClα3B subunit and its 
interactions with agonists, glutamate and ivermectin using electrophysiology to study 
Xenopus oocytes expressing GluClα3B homomeric channels and ligand binding 
studies on COS-7 cells expressing the subunits. Site–directed mutagenesis was 
used to introduce resistance associated candidate polymorphisms into the H. 
contortus GluClα3B subunit. The effects of these changes on the response to 
glutamate and ivermectin were assessed. One mutation found in IVR C. oncophora, 
L256F, confers a 3-fold loss of sensitivity to glutamate and a 6.5 fold loss of 
sensitivity to IVM. This mutation is found in the C-terminal area of the extracellular 
region of the channel and, from homology modelling, we know it lies in close 
proximity and possibly interferes with another candidate mutation V235A, and the 
Cysteine residue at position 192 which forms one side of the structurally significant 
disulphide bridge. Further introduction of different mutations at this position showed 
the larger the substituted amino acid, the greater the effect on IVM sensitivity. 
Another amino acid substitution (T300S) results in the prohibition of a functional 
channel. The protein is produced and is able to bind IVM with high affinity but does 
not create a functional channel. 
These data show that polymorphisms found in field isolates of parasites can have a 
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5-HT    5-hydroxytryptamine 
ACh    Acetylcholine 
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GFP    Green Fluorescent Protein  
GluCl    Glutamate gated chloride channel receptor 
Hc    Haemonchus contortus 
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IVR    Ivermectin Resistant 
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nAChR   Nicotinic acetylcholine receptor 
NMJ    Neuromuscular junction 
NZY buffer   NZ amine yeast buffer 
O.D    Optical Density 
PBS    Phosphate Buffered Saline 
PCR    Polymerase Chain Reaction 
PEI     Polyethyleneimine  
P-gp    P-glycoprotein 
PMSF    (4- bromo) phenylmethylsulphonyl fluoride 
PTX    Picrotoxin 
RE    Restriction Endonuclease  
RNA    Ribonucleic Acid 
RNase    Ribonuclease 
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RT    Room Temperature 
SDS    Sodium Dodecyl Sulphate 
TAE    Tris Acetate EDTA 
Taq    Thermus aquaticus 
TBE    Tris Borate EDTA 
TE    Tris EDTA 




TM    Transmembrane domain 
Unc    Uncoordinated 
UV    Ultraviolet 












List of Abbreviations..............................................................................................................iv 
FIGURES........................................................................................................X 
CHAPTER 1: GENERAL INTRODUCTION.................................................... 1 
1.1 Phylum Nematoda............................................................................................................. 2 
1.1.1 Nematode anatomy...................................................................................................... 3 
1.1.2 The nematode life cycle ............................................................................................... 6 
1.1.3 The nematode nervous system.................................................................................... 8 
1.1.4 Parasitic nematodes..................................................................................................... 9 
1.1.5 Parasitic nematodes and human infection................................................................. 10 
1.1.6 Parasitic nematode infection in animals..................................................................... 13 
1.1.7 Haemonchus contortus .............................................................................................. 14 
1.2 Chemical control of nematodes .................................................................................... 17 
1.2.1 The Benzimidazoles................................................................................................... 18 
1.2.1.1 Benzimidazole resistance ................................................................................... 19 
1.2.2 Imidazothiazoles and anthelmintics that act on nicotinic acetylcholine receptors ..... 20 
1.2.2.1 Resistance to Imidazothiazoles and tetrahydropyridines.................................... 22 
1.2.3 Emodepside ............................................................................................................... 23 
1.2.4 The Macrocyclic lactones........................................................................................... 24 
1.2.4.1 Biological effects of AMs..................................................................................... 26 
1.2.4.2 Human antiparasitic chemotherapy .................................................................... 28 
1.2.4.3 Avermectin Resistance ....................................................................................... 28 
1.3 Cys-loop ligand gated ion channel superfamily .......................................................... 29 
1.3.1 Nicotinic Acetylcholine Receptors.............................................................................. 30 
1.3.1.1 Nicotinic Acetylcholine Receptor structure.......................................................... 32 
1.3.2 GABA receptors ......................................................................................................... 34 
1.3.3 Glutamate-gated chloride channels ........................................................................... 36 
1.3.3.1 Glutamate gated chloride channel pharmacology .............................................. 37 
 viii 
 
1.4 Aim of Project.................................................................................................................. 47 
CHAPTER 2: METHODS AND MATERIALS............................................... 48 
2.1 Materials........................................................................................................................... 49 
2.1.1 Molecular biology reagents ........................................................................................ 49 
2.1.1.2 Composition of general buffers and solutions..................................................... 49 
2.1.1.3 Composition of culture media and buffer ............................................................ 50 
2.1.1.4 Composition of Xenopus oocyte electrophysiology reagents ............................. 50 
2.1.1.5 Bacterial strains................................................................................................... 51 
2.1.1.6 Enzymes ............................................................................................................. 51 
2.1.1.7 Antibiotic solutions .............................................................................................. 52 
2.1.1.8 Mammalian cell-culture reagents ........................................................................ 52 
2.1.1.9 Radioligand binding............................................................................................. 52 
2.2 Basic Methods................................................................................................................. 53 
2.2.1 Agarose gel electrophoresis ...................................................................................... 53 
2.2.2 Restriction endonuclease digestion of DNA............................................................... 53 
2.2.3 Preparation of E. coli competent cells........................................................................ 54 
2.2.4 Transformation of E. coli cells.................................................................................... 54 
2.2.5 Small scale preparation of plasmid DNA ................................................................... 54 
2.2.6 Large scale preparation of plasmid DNA ................................................................... 55 
2.3 Site-directed mutagenesis of GluClα3B cDNA ............................................................ 55 
2.3.1 DNA linearization and site directed mutagenesis ...................................................... 55 
2.3.2 Primer design ............................................................................................................. 56 
2.3.3 Mutagenesis reaction................................................................................................. 56 
2.3.4 Removal of parental dsDNA ...................................................................................... 57 
2.3.5 Transformation of mutated plasmid into supercompetent cells ................................. 57 
2.4 In vitro transcription of cRNA........................................................................................ 58 
2.4.1 DNA linearization ....................................................................................................... 58 
2.4.2 RNA in vitro transcription ........................................................................................... 58 
2.4.3 RNA Reducing gel...................................................................................................... 59 
2.5 Expression of cDNA in Xenopus oocytes for electrophysiology .............................. 60 
2.5.1 Isolation of Xenopus oocytes ..................................................................................... 60 
2.5.2 Injection of oocytes .................................................................................................... 60 
2.5.3 Electrophysiology ....................................................................................................... 61 
 ix 
 
2.5.4 Electrophysiology data analysis................................................................................. 62 
2.6 Expression of GluCl cDNA in mammalian cell lines for ligand binding.................... 62 
2.6.1 Maintenance of COS-7 primate kidney fibroblast cells. ............................................. 62 
2.6.2 Preparation of cells for storage in liquid nitrogen....................................................... 62 
2.6.3 Re-establishment of frozen COS-7 cells.................................................................... 63 
2.6.4 Transfection of COS-7 cells ....................................................................................... 63 
2.6.5 Preparation of membranes from cultured cells .......................................................... 64 
2.6.6 Measuring protein concentration................................................................................ 64 
2.6.7 Binding of [3H]-ivermectin to membrane preparations .............................................. 65 
2.6.8 Radioligand binding data analysis ............................................................................. 66 
2.7 Homology modeling........................................................................................................ 67 
2.7.1 Template search and selection .................................................................................. 67 
2.7.2 Sequence – template alignment ................................................................................ 67 
2.7.3 Model generation ....................................................................................................... 68 
2.7.4 Model Assessment..................................................................................................... 68 
CHAPTER 3: CHARACTERISING THE MOLECULAR PHARMACOLOGY 
OF THE H. CONTORTUS GLUCLΑ3B SUBUNIT. ...................................... 69 
3.1 Introduction ..................................................................................................................... 70 
3.2 Results ............................................................................................................................. 71 
3.2.1 Action of glutamate on oocytes injected with GluClα3B cDNA.................................. 71 
3.2.2 Action of ibotenate on oocytes injected with GluClα3B cDNA................................... 73 
3.2.3 Action of IVM on oocytes injected with GluClα3B cDNA ........................................... 75 
3.2.4 Action of PTX and fipronil on oocytes injected with GluClα3B cDNA........................ 77 
3.2.6 Saturation analysis of [3H]-IVM binding to GluClα3B ................................................ 80 
3.3 Discussion ....................................................................................................................... 82 
CHAPTER 4: ANALYSIS OF THE EFFECT OF SINGLE AMINO ACID 
SUBSTITUTIONS HAVE ON H. CONTORTUS GLUCLΑ3B 
PHARMACOLOGY....................................................................................... 86 
4.1 Introduction ..................................................................................................................... 87 
4.2 Results ............................................................................................................................. 89 
4.2.1 Results of site directed mutagenesis ......................................................................... 89 
 x 
 
4.2.2 Actions of glutamate on oocytes injected with mutated GluClα3B cRNA.................. 91 
4.2.3 Saturation analysis of [3H]-IVM binding to GluClα3B mutants at position 256.......... 93 
4.2.4 Saturation analysis of [3H]-IVM binding to GluClα3B mutants. ................................. 96 
4.3 Discussion ..................................................................................................................... 101 
CHAPTER 5: ANALYSIS OF THE POSITION OF SINGLE AMINO ACID 
SUBSTITUTIONS IN THE N-TERMINAL REGION OF THE H. CONTORTUS 
GLUCLΑ3B SUBUNIT USING HOMOLOGY MODELLING....................... 107 
5.1 Introduction ................................................................................................................... 108 
5.2 Results ........................................................................................................................... 110 
5.2.1 Selecting the template.............................................................................................. 110 
5.2.2 Aligning the sequences............................................................................................ 112 
5.2.3 Building and choosing the models ........................................................................... 116 
5.2.4 Assessing the models .............................................................................................. 116 
5.2.5 Model of GluClα3B V69E mutant. ............................................................................ 119 
5.2.6 Model of GluClα3B E114G mutant........................................................................... 122 
5.2.7 Model of GluClα3B V235A mutant. .......................................................................... 125 
5.2.8 Model of GluClα3B L256F, L256Y, L256W and L256V mutants ............................. 128 
5.3 Discussion ..................................................................................................................... 134 
CHAPTER 6: FINAL DISCUSSION............................................................ 138 
REFERENCES ........................................................................................... 142 
7: APPENDICES ........................................................................................ 162 
7.1 Appendix 1. Map of vector pcDNA3.1 ......................................................................... 163 
7.2 Appendix 2. Primers used for site directed mutagenesis......................................... 164 




Figure 1: Anatomy of an adult hermaphrodite. ............................................................3 
 xi 
 
Figure 2: Nematode body plan with cross sections from head to tail. .........................5 
Figure 3: Basic life cycle pattern of nematodes...........................................................7 
Figure 4: Haemonchus contortus life cycle................................................................15 
Figure 5: Structure of commonly used Benzimidazoles ............................................19 
Figure 6: Chemical structure of the two major nicotinic anthelmintics.......................21 
Figure 7: Structure of amino-acetonitrile derivative- 1470.........................................23 
Figure 8: Structure of emodepside ............................................................................24 
Figure 9: Structure of some avermectins and milbemycins.......................................26 
Figure 10: Tree showing the cys-loop LGIC gene superfamily of C. elegans. ..........30 
Figure 11: Ribbon diagrams of the nACh receptor ....................................................33 
Figure 12: overview of the basic processes involved in the production of GluCl 
channels in Xenopus oocytes....................................................................................61 
Figure 13: Activation of GluClα3B homomeric channels by glutamate. ....................72 
Figure 14: Typical electrophysiological response of GluClα3B homomeric channel to 
ibotenate....................................................................................................................74 
Figure 15:  Activation of GluClα3B homomers by ivermectin (IVM), .........................76 
Figure 16:  Fipronil partially blocks GluClα3B channels irreversibly..........................77 
Figure 17: Picrotoxin blocks homomeric GluClα3B channels reversibly ...................78 
Figure 18.  Raw saturation data of 10 µg COS-7 membrane preparations transiently 
expressing IVS wt GluClα3B with [3H]-IVM. ..............................................................80 
Figure 19: Saturation of COS-7 membrane preparations transiently expressing IVS 
wt GluClα3B with [3H]-IVM.  Inset is the Scatchard plot. ...........................................81 
Figure 20: Comparison Glutamate dose-response curve for oocytes injected with of 
H. contortus (blue) and C. elegans (red) GluClα3B cRNA. .......................................83 
Figure 21: Chromatogram showing sequencing results after successful incorporation 
of a single base change for the mutation E114G. .....................................................91 
Figure 22: Dose-response curves of wild type and mutant dose- response curves for 
glutamate...................................................................................................................93 
Figure 23: Saturation of COS-7 membrane preparations transiently expressing 
mutant GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. .......95 
Figure 24: Saturation of COS-7 membrane preparations transiently expressing 
mutant GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. .......97 
Figure 25: Saturation of COS-7 membrane preparations transiently expressing 
mutant GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. .......98 
Figure 26: Saturation of COS-7 membrane preparations transiently expressing 
mutant GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. .......99 
Figure 27: Saturation of COS-7 membrane preparations transiently expressing 
mutant GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. .....100 
Figure 28: Result of template search for GluClα3B- N-terminal region. ..................111 
Figure 29:  Modeller alignment of GluClα3B N-terminal domain .............................112 
Figure 30: sequence alignment of acetylcholine binding protein (pdb 1I9B) and 
GluClα3B N-terminal domain...................................................................................114 
Figure 31: sequence alignment of acetylcholine binding protein (pdb 1I9B) and 
Mutant GluClα3B N-terminal domain.......................................................................115 
Figure 32: Model of the final wt GluClα3B models ..................................................118 
Figure 33: Model representation of the pentameric homomer of the V69E GluClα3B 
subunit. ....................................................................................................................120 
Figure 34: Model of the GluClα3B N-terminus carrying the V69E mutation ............121 
Figure 35: Model representation of the pentameric homomer of the E114G GluClα3B 
subunit. ....................................................................................................................123 
Figure 36: Model of the GluClα3B N-terminus carrying the E114G mutation..........124 
 xii 
 
Figure 37: Model representation of the pentameric homomer of the V235A GluClα3B 
subunit. ....................................................................................................................126 
Figure 38: Model of the GluClα3B N-terminus carrying the V235A mutation ..........127 
Figure 39: Model representation of the pentameric homomer of the L256 mutant 
GluClα3B subunits...................................................................................................129 
Figure 40: Model of the GluClα3B N-terminus carrying the L256F mutation...........130 
Figure 41: Model of the GluClα3B N-terminus carrying the L256Y mutation ..........131 
Figure 42: Model of the GluClα3B N-terminus carrying the L256V mutation ..........132 
Figure 43: Model of the GluClα3B N-terminus carrying the L256W mutation .........133 








Table 1. Summary of known C. elegans genes, GluCl subunits and expression 
patterns  and the equivalent orthologues in H. contortus. .........................................38 
Table 2. Summary of the pharmacological properties of known C. elegans channels.
..................................................................................................................................39 
Table 3. Summary of the pharmacological properties of known parasitic nematode 
channels expressed in either Xenopus oocytes or COS-7 cells................................40 
Table 4: Summary of GluClα3B subunit sensitivities to glutamate............................83 
Table 5. C. oncophora and H. contortus mutants tested...........................................90 
Table 6. Summary of effects of glutamate on mutant GluClα3B homomeric channels.
..................................................................................................................................92 
Table 7. Summary of Bmax and Kd from radioligand binding studies with [3H]-IVM...101 
Table 8. Evaluation of pentameric template and pentameric models by Modeller 
evaluation scripts.....................................................................................................117 
Table 9. Table summarising the amino acids in contact with V69E in the GluClα3B 
subunit. ....................................................................................................................120 
Table 10. Table summarising the amino acids in contact with E114G in the GluClα3B 
subunit. ....................................................................................................................123 
Table 11. Table summarising the amino acids in contact with V235A in the GluClα3B 
subunit .....................................................................................................................125 











1.1 Phylum Nematoda. 
 
The body of a nematode is long and threadlike and it is from this that the phylum 
gets its name-from the Greek Nema for Thread and Eidos for form. They make up a 
large, successful and fascinating phylum. 
Nematodes are almost unbelievably abundant; within the animal kingdom they are 
second only to arthropods in the number of both species and individuals (Wharton 
1986), with over 20,000 described nematode species in the world with an estimated 
20,000 to 10 million yet to be discovered (Blaxter 1998). 
The nematodes or roundworms are an extremely diverse family that has adapted to 
survive and thrive in a wide range of habitats from compost heaps to desert, salt and 
fresh water and even the permafrost soils of the Arctic and Antarctic tundra. 
Nematode species can feed on a wide range of foodstuffs such as bacteria, fungus 
and algae; they can be omnivores, herbivores, parasites or predators (Wharton 
1986).  Many species live in a number of different environments, whereas others are 
extremely specific about their habitat, a famous example being a nematode only 
found living under the beer soaked felt beer-mats of a few towns in Germany. The 
diversity within the phylum extends to more that just the range of habitats. Different 
nematode species can display a wide array of life cycles from the simple and direct 
to complex parasitic multi-host lifecycles involving different animal hosts and even 
different tissues within those hosts. Nematodes can vary in size from just 0.3mm in 
the length to over 8 metres like Placentonema gigantisma, a nematode discovered in 
in 1950 in the placenta of a sperm whale and noted to have 32 ovaries (Gubanov 
1951).  
Approximately half of the known nematode species are free living and carry out 
essential roles in the ecosystem such as contributing to the decomposition of 
vegetation. The remaining nematodes are classed as parasitic and inhabit a wide 
range of hosts. Some prey on plants, others fish, reptiles, birds, insects and 
mammals. There are few species in the world completely free from parasitic 





1.1.1 Nematode anatomy  
 
Despite adaptations to their individual environments, all nematodes are built around 
similar, characteristic anatomical structures which are conserved through out the 
phylum. The body of the typical nematode is a flexible cylinder which tapers at each 
end, with a pointed tail and a blunt head (White et al. 1986). 
 Nematode anatomy has been most closely studied in the free living nematode 
Caenorhabditis elegans which is widely used a model organism and the large- easily 
dissected parasitic nematode Ascaris suum.  The nematode anatomy is generated 







Figure 1: Anatomy of an adult hermaphrodite.  
A. DIC image of an adult hermaphrodite on left lateral side. Scale bar 0.1 mm.  
B. Schematic drawing of anatomical structures on left lateral side. Dotted lines and 






Nematodes are bounded by the strong but flexible collagenous extracellular cuticle 
which lines the animal completely including any invaginations and which is shed at 
the end of each larval stage. Beneath the cuticle is a hypodermis which may be 
either cellular or syncytial (White et al. 1986). The basic plan of the internal 
nematode body has been described as “a tube within a tube” and consists of two 
concentric tubes separated by a fluid-filled space which maintains the shape of the 
nematode using internal hydrostatic pressure known as the pseudocoelom (see 
Figure 2) (Riddle et al. 1997) although there are a few exceptions such as the 
monohysterid marine nematode, Theristis, which lacks a pseudocoelom. The outer 
tube contains the secretory/excretory components, nervous system, the gonad and 
the coelomocytes. The excretory/secretory system is involved in osmoregulation 
which is essential to the maintenance of the structural integrity of the nematode. The 
excretory cell is the largest cell in the animal, with excretory canals running the 
length of the body that are connected to an excretory/secretory pore on the ventral 
side of the head, which is responsible for the secretion of glycoproteins thought to 
make up a surface coat over the cuticle. This coat acts as a protective barrier, 
protecting the nematode from infection and, in the case of parasites, protects from 
invasion by a host immune system. The layers of body wall musculature are 
attached to the cuticle via a thin layer of hypodermis. The nematode muscle is 
similar in structure to vertebrate striated muscle and insect flight muscle but Z bands 
are not present. The musculature is arranged in four longitudinal strips, and it is 
contraction of the two subventral muscle strips with relaxation of the corresponding 
subdorsal strips, and vice versa that generates the characteristic sinusoidal 
movement in the dorsal-ventral plane (Sulston et al. 1988). The inner tube primarily 
comprises of the digestive system. Nematodes have a complete digestive system. 
The nematode digestive system is generally divided into three parts, the stomodeum, 
intestine, and proctodeum. The stomodeum consists of the “mouth and lips”, buccal 








Figure 2: Nematode body plan with cross sections from head to tail.  
Approximate level of each cross section is labelled in Figure 1. taken from (Altun et al. 2005) 
A. Posterior body region. Body wall (outer tube) is separated from the inner tube (alimentary 
system, gonad) by a pseudocoelom. Orange lines indicate basal laminae.  
B. Section through anterior head. The narrow space between the pharynx and the 
surrounding tissues anterior to the NR can be considered an accessory pseudocoelom since 
the main pseudocoelom is sealed off by the GLRs at the NR level.  
C. Section through the middle of head.  
D. Section through posterior head.  
E. Section through posterior body. DNC: Dorsal nerve cord; VNC: Ventral nerve cord.  





The pharynx is a variable and highly muscular organ that usually contains several 
enlargements (bulbs) and lies posterior to the mouth behind the buccal cavity, which 
is highly variable in size and structure between nematode species to the extent that 
the buccal cavity and pharynx are used extensively in taxonomy and classification of 
nematodes, as well as providing as indication of feeding habit or trophic group, for 
example, the buccal cavity of plant parasitic nematodes (and some insect parasites) 
is modified in the form of a hollow spear, adapted to penetrate and withdraw the 
contents of host cells. Predaceous nematodes often have a buccal cavity 
characterized by teeth or hook-like projections. The pharynx is primarily a pumping 
organ and acts by contraction of the buccal and anterior pharyngeal muscles which 
force the mouth open and cause dilation of the anterior of the pharynx. This 
produces a negative pressure gradient causing food and outside material into the 
mouth. Then the high hydrostatic pressure applied from the pseudocoelom acts to 
close the mouth and the oesophageal lumen when the muscles relax creating the 
characteristic sucking/pumping action. The food passes through a second bulb which 
grinds it, breaking up the food source e.g. opening blood cells or rupturing bacterial 
cell walls etc to create a directly digestible pulp. The intestinal cells surround a 
central lumen which connects to the anus (Riddle et al. 1997) These intestinal cells 
are not muscular and food debris is forced through the intestine and toward the 
rectum by the pharyngeal pumping, The anus is opened via contraction of anal 
dilator muscles and closed by the turgor of the internal hydrostatic pressure.   
 
1.1.2 The nematode life cycle 
 
The typical life cycle of the nematode is made up of six distinct stages, the egg 
followed by four larval stages known as L1-L4, and the adult stage (see figure 3). 
Some species undergo their first moult while still in the egg and hatch as second-
stage larvae (Bird et al. 1991).  The process and purpose of moulting is an area of 
conflict. Moulting has been proven to have little effect on the growth curve (Wharton 
1986; White et al. 1986). The large intestinal parasite Ascaris is only slightly larger 
than C. elegans at its final molt, but it undergoes a massive increase in size as an 
adult. The act of moulting allows the nematode the opportunity to replace and modify 
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the cuticle and this necessity to change surface composition to survive changing 
environments is one explanation for moulting in the parasitic nematodes (Blaxter et 
al. 1992). For free-living nematodes the moulting cycle has been proven to trigger 
basic developmental cues controlling postembryonic cell lineages, and 






Figure 3: Basic life cycle pattern of nematodes. 
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1.1.3 The nematode nervous system 
 
Most of our understanding of the nematode nervous system and neurobiology stems 
from the extensive study of the tiny free living C. elegans and the much larger 
parasitic nematode Ascaris suum. The striking similarities between the nervous 
systems of these two very different nematodes suggest there is a high level of 
continuity within the phylum. 
The nematode nervous system consists of a set of parallel interconnected neuronal 
processes that run the length of the nematode body, or circle the nematode body 
adjacent to the hypodermis. The nerve bundles in the nematode body run through 
the ventral cord (part of the hypodermis), but nematodes also have nerves in the 
dorsal cord, the two lateral cords and the nerve ring. The nervous system can be 
split into two near autonomous units, the pharyngeal and somatic nervous systems. 
(Chalfie et al. 1988). The pharyngeal nervous systems contains about 20 neurons 
and is responsible for control of pharyngeal pumping, in experiments when the 
pharynx is removed from the rest of they body or destroyed it will continue pump 
demonstrating it’s myogenic nature (Avery et al. 1989). There is a level of 
communication between the somatic and pharyngeal nervous systems via by a pair 
of neurons known in C. elegans as RIP cells. 
The cell bodies of most neurons are positioned around the pharynx, along the ventral 
midline and in the tail. Most of their cell processes form a ring around the basement 
membrane that surrounds the pharynx, or they join the dorsal or ventral nerve cords 
as in the somatic nervous system. Most chemosensory and mechanosensory 
neurons extend afferent processes from the region of the nerve ring to sensory 
organs near the tip of the head. Other sensory neurons extend their processes along 
the body or to the tail. The nerve ring receives and integrates sensory information 
and connects to motor neurons in the head or along the nerve cords (Riddle et al. 
1997). 
The first complete study of the nematode nervous system was published in 1986 in a 
massive 340 page paper. The study of the C. elegans nervous system involved the 
painstaking reconstruction of thousands of electron micrographs of serial sections. 
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This showed the presence of 302 component neurones (A. suum has 298). The 
neurones could then be classed into 118 groups with similar morphologies and 
connectivities (White et al. 1986). 
The basic neuron structure proved to be very simple with few branches that often 
made up nerve processes that run in bundles (like the nerve ring) following defined 
routes in defined positions, the bundles often run adjacent to the ridges of 
hypodermis (as in the dorsal and ventral nerve cords). The 1986 reconstruction 
yielded not only a connectivity pattern, but also an excellent understanding of the 
structure of synapses in C. elegans. It described most of the morphologically 
identifiable synaptic connections in a typical animal. These consist of about 5000 
chemical synapses, 2000 neuromuscular junctions and 600 gap junctions (White et 
al. 1986; Rand et al. 1997). 
 
The neuromuscular processes in the nematode are unique in that instead of the 
nerves   forming processes and reaching out to the muscles the opposite is true with 
the muscle fibres producing muscle arms which grow to meet the neurons (White et 
al. 1986). Neurons are generally highly locally connected, making synaptic 
connections with many of their neighbours. It has also been showed that the 
specificity of synaptic contacts made by individual neurons was relatively conserved 
from nematode to nematode (White et al. 1986; Hall et al. 1991). 
 
 
1.1.4 Parasitic nematodes. 
 
 
Half of all known nematode species are parasitic, infecting and living off plants, 
animals (invertebrates, vertebrates, terrestrial and aquatic) and, of course, humans. 
In plants parasitic nematodes have a catastrophic effect on the crop harvests around 
the world The cost of the loss of crops due to nematodes has been put at £100 
billion per year (Amoussou et al. 2004). Nematodes, in particular Meloidogyne spp 
and Globodera spp, cause 12% reduction in the world potato harvest. This 
represents the loss of 35 million tonnes world-wide, of which 13 million tonnes are 
lost in the developing world, particularly in poor areas of South America where potato 
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is a primary source of carbohydrate. Nematode infestations vary in severity and 
Individual losses can be higher than this average both nationally and locally, Higher 
infestations occur particularly in poorer areas due to the lack of access to the 




Of those parasitic nematodes that infect vertebrates, the vast majority are the soil-
transmitted nematode parasites, or geohelminths, so called because they have a 
direct life cycle, which involves no intermediate hosts or vectors, and are transmitted 
by faecal contamination of soil, foodstuffs and water supplies (Holland et al. 2002). 
The primary members of this group are the Ascaris, Trichus and hookworm species. 
The adult geohelminths inhabit the intestine or the stomach of the host, where they 
compete with the host for nutrients. Infection causes anaemia, malnutrition which 
leads to further complications such as stunted growth, physical weakness and a 
weakened immune system. Most species also have tissue-migratory juvenile stages, 
so the disease manifestations they cause can therefore be both local and systemic, 
and often causing serious complications due to ectopic establishment of nematodes.  
A second, important group of parasitic nematodes that cause infection in vertebrates 
are the filaria, a group of closely related nematodes that are tissue dwelling and long 
lived; transmission of filaria requires an intermediate host, usually a biting arthropod. 
The human diseases caused by filarial nematodes include Onchocerciasis caused 
by Onchocerca volvulus and Lyphantic filariasis caused by Wucheria bancrofti and 













Over 342 species of helminths have been found in association with humans, of 
which 138 are nematodes (Crompton 1999). Of all the helminths 197 would be 
considered as primarily inhabitants of the gastrointestinal (GI) tract. Many are 
harmless and are likely to be due to accidental infections from other species that are 
normal hosts or perhaps, in some communities, even commensal in the GI tract.  
Around 20 species are considered to cause disease, of which six (Enterobius, 
Ascaris, Necator, Ancylostoma, Trichuris and Strongyloides) together affect over half 
of the world's population (Horton 2003).   
 
It has been reported that 1.3 billion people in the world are  infected with hookworms 
(either Ancylostoma duodenale and Necator americanus) (Pawlowski et al. 1991; 
Chan et al. 1994; Crompton 1999). Although hookworm is rarely fatal it is still a 
leading cause of maternal and child morbidity in the developing countries of the 
tropics and subtropics. In susceptible children hookworms cause anemia and 
malnutrition causing retardation of intellectual and cognitive development and 
stunted growth. Poor iron status and iron deficiency anaemia are the hallmarks of 
hookworm disease. In the developing foetus of an infected mother often suffers 
intrauterine growth retardation, premature birth, and low birth weight. Hookworm 
infection is rarely fatal when looked at as a percentage of people infected, but due to 
the number of people infected it still accounts for the deaths of 65,000 people per 
annum, usually due to significant anemia in the heavily infected individual (Crompton 
1999).  
Ascaris lumbricoides, the most frequent human intestinal nematode, is the causative 
agent of ascariasis, with an estimated worldwide prevalence of over 1472 million 
people (~25% of the world’s population) (Crompton 1988; Chan et al. 1994; Peng et 
al. 1998; Crompton 1999), It is primarily found in moist tropical and subtropical 
regions, but is also found in cooler climates. Reduced food intake, impaired 
digestion, malabsorption, and poor growth rate are frequently observed in children 
suffering from ascariasis and trichuriasis (Crompton et al. 2002). Although 
characterised with proportionally low mortality rates, the global prevalence of 
ascariasis still results in approximately 60,000- 100,000 deaths annually (Crompton 
1999), primarily as a consequence of intestinal obstruction. In humans, transmission 
of infective eggs usually occurs by hand-to-mouth route by way of faecal 
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contamination through agricultural products and food, or from dirty hands due to poor 
sanitation. Three phases of ascariasis may be present, pulmonary, intestinal and 
complications stages (Georgiev 2001). Pulmonary disease is caused by the 
migration of the juvenile nematodes through tissues to the lungs causing 
haemorrhage and oedema.  The resulting accumulation of fluids in the lungs results 
in "ascaris pneumonia", and along with the partial or complete obstruction of biliary 
or intestinal tracts can, in rare cases, cause death.   
 
Another problematic parasitic nematode of humans is the filarial nematode 
Onchocerca volvulus. Transmission occurs through bites of vector blackflies in the 
family Simuliidae. Although a few vector species breed in slow-moving streams, 
most require fast-flowing, highly oxygenated streams or rivers leading to high 
prevalence of disease in these areas. For this reason, ocular onchocerciasis is often 
called "river blindness." The most serious clinical manifestation of onchocerciasis is 
blindness, caused by microfilariae that wander into the eye. In endemic areas, 
corneal opacities resulting from the reaction to dying microfilariae often suggest 
onchocercal infection. Alternatively, active living microfilariae may be seen when the 
eye is examined with a slit lamp (Baron et al. 1996). Onchocerciasis is prevalent in 
many parts of tropical Africa and has been reported in a few places in the Middle 
East. In the Americas, it is an important and widespread infection in Guatemala and 
the southern states of Mexico. It also appears in other areas of Central America, and 
a few foci have been found in Venezuela, Colombia, Surinam, Brazil, and Ecuador. 
In addition to visual impairment, onchocerciasis is associated with serious 
pathological changes of skin. There is a great deal of discrepancy over levels of 
infection worldwide. According to some sources total of 18 million people are 
infected with the disease and have dermal microfilariae, of which 99% are in Africa. 
45,000 fatalities per year are attributed to onchocerciasis and over 500,000 are 
thought to be blind or severely visually impaired (Molyneux et al. 1997; Crompton 
1999; Basanez et al. 2006). Other surveys show that the WHO figures are an 
underestimate of the extent of disease—37 million people are now thought to be 
infected, with 90 million at risk in Africa and more than 400 000 infected in Central 




In lymphatic filariasis, disease is caused by the presence of one of several types of 
nematode in the regional lymphatic vessels and, particularly, by the host response to 
the nematode and nematode products. The microfilariae are released into the blood. 
Infections involving small numbers of worms are often asymptomatic. Early 
symptoms of lymphatic filariasis consist of intermittent fever and enlarged, tender 
lymph nodes. The inguinal lymph nodes are very often involved. The lymphatic 
vessels that drain into the lymph nodes and that harbour the developing and adult 
worms also become inflamed and painful. In more chronic infections, there may be 
pain also in the epididymis and testes. Swollen lymphatics may burst and drain into 
the genitourinary system resulting in chyluria (milky urine) (Baron et al. 1996) In a 
small number of chronic cases, permanent lymphatic dysfunction caused by 
repeated exposure to infection over a number of years results in the massive 
lymphedema and accumulation of excess tissue known as elephantiasis). Lymphatic 
filariasis is most commonly caused by the nematodes Wuchereria bancrofti and 
Brugia malayi, amongst others, depending on geographical origin and is transmitted 
by a feeding vector mosquito. It is one of the world's most disfiguring and debilitating 
parasitic diseases. Over 120 million people are afflicted in 83 countries (WHO 2000).  
 
1.1.6 Parasitic nematode infection in animals. 
 
 
Nematodes are also important parasites of livestock and companion animals. A. 
suum is a large intestinal worm very similar to the human parasite A. lumbricoides 
described above, and it is the causative nematode of ascariasis in swine. Like A. 
lumbricoides, A. suum has a direct life cycle with the primary infection caused by 
ingestion of viable fertilised eggs in food or water. 
As with A. lumbricoides, A. suum larvae hatch in the small intestine and the juveniles 
can migrate through the tissue of the intestinal wall and through to the heart; lungs to 
the trachea and larynx where they are often re-swallowed and return to the intestine 
(Campbell 1981; Baron et al. 1996). The female produces between 200- 200,000 
eggs per day which are released from the animal in faeces. The eggs alone can 
survive for up to seven years (Smyth 1994) and the longevity and the sheer number 
of the eggs means that the level of re-infection of both A. lumbricoides and A. suum  
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is very high. Although the mortality rate for pigs with A. suum infections is relatively 
low, the morbidity is high with the animals losing condition due to diarrhoea, 
malnutrition and intestinal blockage. Re-infection of juveniles in the porcine lungs 
can result in allergic broncho-pneumonia. As the aim of pig farming is to gain the 
largest muscle mass per animal possible, the competition for nutrients is financially 
damaging to the farmer.  
D. immitis is a filarial worm known as the dog heartworm and is found in the right 
hand chambers of the heart and the adjacent blood vessels, particularly the 
pulmonary arteries. In chronic infections it results in pulmonary hypertension leading 
to right sided heart failure (Knight 1987). It primarily affects domesticated dogs and 
sometimes cats; other wild carnivores such as ferrets, dogs and foxes may act as 
reservoirs for potential infection.  
Microfilariae are carried from the heart through the lungs and into the systemic 
bloodstream, from where a mosquito can take a blood meal. Within the mosquito 
digestive system the microfilariae moult and develop into infective L3-stage larvae 
which are passed into a new carnivorous host with a second blood meal by the 
mosquito. Zoonosis is rare but can occur with D. immitis if the second blood meal is 
from a human. 
 
1.1.7 Haemonchus contortus  
 
 
The members of the family Tristrongylidae are parasites of the mammalian small 
intestine. Such nematodes include Ostertagia spp. and Haemonchus contortus 
commonly known as the “barber pole” worm.  The common name originates from the 
characteristic red and white stripes of the female formed as the ovaries wrap around 
the intestines which are red from blood feeding.  
 
H. contortus is a parasite of the digestive tract of ruminants and as a result costs the 
grazing livestock industry hundreds of millions of dollars worldwide in production 
losses and treatments and accounts for the vast majority of Australia’s 1994 
expenditure of AUS$ 222 million on sheep nematodes (McLeod 1995). 
As with all geohelminths no intermediate host is required. Adult male and female 
worms live in the abomasum (or true stomach) of ruminant animals. The female 
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deposits 5,000 to 10,000 eggs per day which pass out of the host with the faeces. 
First stage (L-1) juveniles hatch from the eggs in the warm moist conditions of the 
animal faeces. First and second stage juveniles feed on soil dwelling bacteria.  By 
the time the L-3 stage they are infective for the vertebrate host, cannot feed and 
retain the second stage cuticle as a sheath. The ruminant becomes infected while 
grazing by eating the L-3 juveniles which migrate up blades of grass and other 
vegetation is order to be ingested. Ex-sheathment occurs in the rumen, anterior to 
the abomasum, and the young fourth-stage (L-4) worms pass into the abomasum 
where they burrow into the mucosa. Here they undergo another moult, and the 
juveniles come back into the paramucosal lumen of the abomasum. They begin to 
feed on the blood vessel rich area of the stomach epithelia and undergo another 




Figure 4: Haemonchus contortus life cycle 
 
Each worm is relatively small (The males are 10 to 20 mm and the females 18 to 30 
mm long) but can consume up to 15 μl of blood per day and with a single infestation 
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carrying thousands of worms, this blood loss is significant. In a sudden acute 
infestation in smaller ruminants such as young lambs that are most susceptible, the 
blood loss can be fatal. In rare cases of hyperacute haemonchosis, sudden deaths in 
a flock of previously healthy sheep are seen. This syndrome results from ingestion of 
large numbers of infective larvae by sheep grazing on a heavily contaminated 
pasture. It often follows a period of warm, wet weather during which massive 
numbers of Haemonchus eggs develop rapidly to infective stages. Post mortem 
examination shows large numbers of worms in the abomasum - anywhere from 
20,000 to as many as 50,000 have been reported (Johnstone 1998) 
In chronic infestations the animals suffer from anaemia, weight loss and loss of 
condition resulting in loss of milk productivity in dairy cows, lower quality wool in 
sheep and goats and smaller malnourished animals for slaughter, consequentially 
there is a monetary loss to the farmer. Animals can fight back against a H. contortus 
infection by a phenomenon known as “self cure” which is common in sheep in 
endemic areas. Significant acquired immunity to H. contortus can be seen in sheep 
older than 6 months, but this immunity is not absolute, and sheep in endemic areas 
may remain susceptible throughout their lives. "Self-cure" is the periodic natural 
expulsion of adult H. contortus from sheep and appears to have an immunological 
basis; there is a steep increase in the level of the serum antibodies IgG and IgA. A 
response to excretory secretory antigens resulting in an increase of the specific 
antibody IgE (Newton et al. 1999).  The elimination of L3 worms from immune sheep 
is now thought to be as a result of eosinophils (Meeusen 1999). A  type 1 immediate 
hypersensitivity response such as an mild allergic reaction provoked by antigens 
secreted by developing larvae has been credited with causing nematode expulsion 
(Miller 1984; Miller 1996). However, self-cure induced by a challenge infection is not 
always followed by protection since larvae in the  challenge infection may develop to 





1.2 Chemical control of nematodes 
 
 
Since the discovery of the first of the three major classes of anthelmintics there have 
been significant advances in the treatment of helminth infections in humans and in 
domesticated animals rendering the vast majority of infections fully treatable. Human 
helminth control programmes have also been shown to have important impacts on 
measures such as nutrition and cognition at the population level (Reynoldson et al. 
1997; Sacko et al. 1999; Horton 2003). Chemotherapy is the most commonly used 
form of nematocidal control. Discovery of drug-target sites that are pharmacologically 
distinct from those of the host have been fundamental in the in the production of high 
potency, broad spectrum drugs that are up to 100% effective at removing worm 
burdens. In 1994 it cost the British farming industry £1 billion to treat parasitic 
gastroenteritis caused by parasites such as H. contortus (Newton et al. 1999). The 
vast majority of this money went on anthelmintics. Treatment of animals with 
parasitic infections can be highly successful. There are several types of drug on the 
market for the treatment of nematode infections, one of the most important are the 
avermectins, which are used with great success to treat all of the nematodes 
discussed thus far in both humans and animals. In 1999 anti-parasitic drugs 
accounted for 13% and 39% of expenditure in the world livestock and companion 
animal product sales respectively (Witty 1999). 
There are three major classes of drugs that take over 90% share of the anthelmintic 
market: the benzimidazoles (BZ) make US$ 365 million per year (1999 figures) the 
imidazothiazoles US$ 260 million, but, the avermectins/milbemycins (AM) command 
the greatest market share bringing in US$ 995 million per year (Witty 1999). More 
recently, the BZ, albendazole (ABZ) is being administered widely in combination with 
either diethylcarbamazine (DEC) or ivermectin (IVM) as part of the Global Program 
to Eliminate Lymphatic Filariasis (GPELF). Many hundreds of millions of doses of 






1.2.1 The Benzimidazoles  
 
Thiabendazole was discovered in 1964, and proven to have a highly effective 
antifungal activity in addition to being a highly potent broad spectrum anthelmintic 
(Conway 1964).  Over time thiabendazole was modified and improved upon to create  
a whole class of drugs  called then benzimidazoles (BZ) that included other, more 
potent compounds such as albendazole, mebendazole, fenbendazole and 
triclabendazole amongst others They all composed of a bicyclic ring system 
containing a benzene fused to the 4- and 5- position of a heterocyclic compound (de 
Silva et al. 1997). (See figure 5).   
 The mode of action of the benzimidazoles has been investigated and well 
characterised.  Initally it was reported that treatment with the BZs resulted in damage 
to the intestinal walls of the nematodes, a loss of cytoplasmic tubules, prevention of 
secretory vesicle transportation and inhibition of glucose uptake. As a result the 
nematodes die of starvation (Lacey 1990; Lubega et al. 1991; Lubega et al. 1991; 
Beugnet et al. 1996). This is because the benzimidazoles bind directly to the β-
tubulin monomer of nematodes, causing inhibition of the proliferation of polymeric 
microtubules by addition of α-/β-tubulin heterodimers and interfering with microtubule 
dynamics and consequently disturbing the essential microtubule-based processes in 
these helminths (Enos et al. 1990; Lacey 1990; Lubega et al. 1991; Lubega et al. 
1991; Beugnet et al. 1996; Jasmer et al. 2000; Robinson et al. 2004).  The helminth 
intestinal damage that is observed is due to the BZ causing ectopic release of 
release of digestion enzymes causing damage to the intestine surface and 
component cells, which, in turn prevents digestion of food, nutrients being absorbed 
by the gut and results in starvation.  Experiments with C. elegans has also shown 
suggests that treatment with BZ also causes retardation in oocyte formation due to 
the necessity for a competent and complete cytoskeleton in order to complete 
meiosis (Enos et al. 1990; Beugnet et al. 1996).   Effects of BZ can also be found in 
the mitochondria where an uncoupling of oxidative phosphorylation  causes 








Figure 5: Structure of commonly used Benzimidazoles 
 
1.2.1.1 Benzimidazole resistance 
 
Benzimidazole (BZ) resistance started to appear in veterinary nematode parasites 
soon after the introduction of thiabendazole, the first BZ.  Veterinary resistance has 
become such a large problem that several recent field studies have demonstrated 







least 50%, and in some countries >90%, of tested farms showing signs of resistance 
(Bauer et al. 1986; Varady et al. 2000; Çirak et al. 2004; Wirtherle et al. 2004; Von 
Samson-Himmelstjerna et al. 2007).  
 
Much work has been done to understand the mechanism of BZ resistance. It has 
been observed that a number of naturally occurring β-tubulin mutations have been 
shown to be associated with BZ resistance in parasitic nematodes. It has been 
discovered that point mutations in the β-tubulin isotype 1 gene leading to amino acid 
substitutions at codons 167, 198, and 200 confer resistance. The best documented 
of these is the phenylalanine-to-tyrosine substitution at position 200 on the β-tubulin 
isotype-I and  β-tubulin isotype-II molecule of Haemonchus contortus (Kwa et al. 
1994; Prichard 2001). Similarly, a phenylalanine-to-tyrosine or histidine substitution 
at position 167 is also found in BZM-resistant trichostrongylid nematodes (Prichard 
2001; Silvestre et al. 2002). Finally, recent evidence suggests that a third mutation in 
isotype 1 can also contribute to BZ resistance in H. contortus (Ghisi et al. 2007) an 
adenine-to-cytosine transversion has been identified that leads to a glutamate-to-
alanine polymorphism at codon 198 in BZ-resistant populations from Australia and 
South Africa (Ghisi et al. 2007; Von Samson-Himmelstjerna et al. 2007).  
 
1.2.2 Imidazothiazoles and anthelmintics that act on nicotinic 
acetylcholine receptors   
 
 
The Imidazothiazoles (levamisole) and tetrahydropyridines (pyrantel and morantel) 
(see figure 6) are two classes of highly effective broad spectrum anthelmintics, first 
used in livestock in the mid to late 1960s (Guilhon 1966; Brimblecombe et al. 1969; 
Turton 1969).  These compounds all act on the nicotinic acetylcholine receptors 
found in nematode muscle with high affinity, but only have a low level of activity at 
the vertebrate nAChRs making them an ideal drug with a high efficacy against 
nematodes but low toxicity to the host. In the nematode addition of Imidazothiazoles 
and tetrahydropyridines opens ACh-gated cation-selective ion channels, which 
constitute the nAChRs, on nematode muscle membranes, producing a 
depolarization and causing muscle contraction and spastic paralysis in treated 
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nematodes. This was discovered in experiments using pyrantel carried out on 
Ascaris suum. The large size of this particular nematode is convenient allowing 
dissection of large, individual, muscle strips or cells to carry out contractile assays on 
(Aubry et al. 1970).  This effect was later confirmed in other nematode species H. 
contortus (Sangster et al. 1991) and C. elegans (Lewis et al. 1980).  Pyrantel and its 
analogues (including morantel) caused a slowly developing contracture of strip 
preparations of Ascaris, being more than 100 times more potent than acetylcholine. 
Pyrantel also caused depolarization and increased spike discharge frequency in 
single muscle cells, these changes being accompanied by increase in tension (Aubry 
et al. 1970). Later electrophysiological readings showed an increase in the input 
conductance of the membrane to potassium and sodium has also been shown on 
addition of pyrantel or levamisole. This effect is also seen with application of 
acetylcholine, although, the anthelmintics had a more potent effect (Harrow et al. 











1.2.2.1 Resistance to Imidazothiazoles and tetrahydropyridines 
 
As with the BZ family resistance to the Imidazothiazoles and tetrahydropyridines is 
becoming a more common occurrence  (Sangster et al. 2002; Martin R et al. 2007) 
and is now recognized in parasites of both humans and domesticated animals. 
Unlike BZ resistance to cholinergic agonists is not caused by a few amino acid 
substitutions. It seems the mechanism for resistance is more complex and may be 
produced by a combination of four general mechanisms, increased metabolism or 
excretion of the drug, a reduced number of susceptible receptors, post-receptor 
modification or a change in receptor binding sites due to amino acid substitution. 
Some amino acid substitutions have been implicated in resistance to the nicotinic 
agonists such as E153G mutations in UNC-38  and Q57G mutations in UNC-63 
(both proteins are nAChR α-subunits) from C. elegans (Rayes et al. 2004; Bartos et 
al. 2006; Martin R et al. 2007). All of these mechanisms could play a role in 
resistance to levamisole and pyrantel and so it is anticipated that resistance to these 
drugs is polygenic (Sangster et al. 2002). 
 
A new class of broad spectrum anthelmintics that act on nematode nAChRs has 
been described. The amino-acetonitrile derivatives (AADs) are a class of low 
molecular mass compounds that are easily accessible by alkylation of phenols with 
chloroacetone, Strecker reaction and acylation of the amine with aroyl chlorides (see 
figure 7) (Kaminsky et al. 2008).  The AADs act on nematode specific nAChR 
subunits including DEG-3, and is effective in nematodes resistant to levamisole and 
pyrantel and other multidrug-resistant parasites. This is claimed to be due to a 
presumed activation of signalling via nematode-specific DEG-3 subtype nAChRs 
(Kaminsky et al. 2008).  Commercial use of AADs is still some years off and if it is 
successfully brought to market there is little doubt that resistance to AADs will 
emerge in the future, but proper management of the drug and its distribution and use 







Figure 7: Structure of amino-acetonitrile derivative- 1470 
Modified from figure (Kaminsky et al. 2008) 
 
1.2.3 Emodepside  
 
 
Emodepside is a relatively new anthelmintic on the market. Developed in the 1990’s, 
it is a derivative of a fermentation product of Mycelia sterilia, a fungus found on the 
shrub  Camelia japonica (Holden-Dye et al. 2007). The effects on C. elegans include 
inhibition of pharyngeal pumping, decreased locomotion general retardation of 
development and inhibition of egg-laying resulting in “bagging” in adult 
hermaphrodites. Emodepside acts through latrophillins, in particular the LAT-1 gene, 
which mediates the inhibitory effects on feeding and locomotion. RNAi knockout 
studies  (Willson et al. 2004; Bull et al. 2007; Guest et al. 2007) determined that the 
lat-1 mutants show a level of reduced sensitivity to emodepside but also exhibit the 
same locomotor inhibition (Guest et al. 2007). Emodepside has  also been linked to 
the SLO-1 calcium activated potassium channel (Wang et al. 2001). It is thought that 
emodepside activates a SLO-1-dependent pathway; null mutants of the slo-1 gene 
are highly resistant to the emodepside effects on locomotion and feeding. In addition, 
strains carrying gain-of-function alleles of slo-1 genes behave in the same way as 
emodepside treated animals but are not emodepside hypersensitive (Holden-Dye et 
al. 2007). The fact that emodepside appears to act on novel drug targets shows that 
it may be an excellent alternative to the classic three drug classes that overwhelm 
the market. As resistance to the benzimidazoles, nAChRs agonists and the 
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macrocyclic lactones becomes increasingly widespread, new drugs are needed. 
Emodepside has proven effective on nematodes from populations resistant to 
benzimidazole, levamisole and ivermectin (Harder et al. 2002) indicating that it will 









1.2.4 The Macrocyclic lactones  
 
The avermectins (AVMs) and the milbemycins are two structurally related drug 
classes’ macrocyclic lactones that possess potent anthelmintic, insecticide and 
acaricide properties. 
Both the AVMs and milbemycins (AM) were discovered due to a large scale 
screening program at Merck in the mid 1970’s (Vercruysse et al. 2002), by which 
bacterial and fungal fermentations were sequentially tested for any antihelmintic 
properties. The avermectins were famously derived from the microorganism 
Streptomyces avermitilis isolated from a soil sample taken from a bunker on a 
Japanese golf course in 1976. Once proven to have antiparasitic properties several 
synthetic derivates with enhanced therapeutic properties were produced and are 
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known collectively as “The Avermectins”. The first commercial use of these 
compounds came in 1981 when ivermectin was cleared for use in animals. 
Ivermectin (a mixture of two compounds, 22, 23 di-hydroavermectin B1a and 22,23-
dihydroavermectin B1b) are semi-synthetic derivatives of avermectin B1a, which of 
the 8 originally isolated avermectin had proved to have the most potent antihelmintic 
properties (Chabala et al. 1980; Egerton et al. 1980).  Other avermectins have been 
introduced over the years, all contain the same basic structure such as doramectin 
from Pfizer, abermectin designed as an injectable agent in cattle and eprinomectin 
for use in lactating dairy cows (Vercruysse et al. 2002)  and Moxidectin, a 
milbemycin produced by Fort Dodge. 
The AVMs are characterised by their broad spectrum activity and are used to combat 
nematode infections in humans, animals and crops. Avermectins are used as an 
insecticide, the most common being abermectin  (Ali et al. 1985), although in the last 
three years new synthetic avermectin derivatives have also been created for the 





Figure 9: Structure of some avermectins and milbemycins  
 
1.2.4.1 Biological effects of AMs 
 
 
The AMs can have an effect on several different sites, but it is widely believed that 
the major effective site of action is the glutamate-gated chloride channel (GluCl). 






seen to non-competitivley block GABA receptors in Ascaris muscle at micromolar 
concentrations (Holden-Dye et al. 1988; Holden-Dye et al. 1990), but the relatively 
high concentrations of IVM required to elicit a reposnse on GABA receptors indicate 
that they were not the primary drug target in nematodes (Martin et al. 1989; 
Schaeffer et al. 1989). IVM has been also reported to act as an allosteric modulator 
of nicotinic α7 subunits. It was shown that preapplication of IVM, in the micromolar 
range, strongly enhances the subsequent acetylcholine-evoked current of the 
neuronal chick or human α7 nicotinic acetylcholine receptors expressed in Xenopus 
oocytes and K-28 cells (Krause et al. 1998), it was later shown to have the same 
effect on the C. elegans nAChR subunit UNC-16 (Raymond et al. 2000).  However, it 
was investigations into the site of action of a the AMs on C. elegans membranes and 
rat brain and the discovery of high affinity binding sites that first lead to the 
suggestion that GluCls were present and IVM sensitive (Schaeffer et al. 1989). 
A number of in vitro studies have shown that AMs inhibit motility, fecundity and 
pharyngeal pumping in nematodes (therefore halting feeding) (Pemberton et al. 
2001). Inhibition of pharyngeal feeding is the most sensitive of the AM sensitive 
processes (Gill et al. 1991; Geary et al. 1993; Gill et al. 1995; Paiement et al. 1999) 
with a concentration of  ≥ 0.1nM IVM causing complete paralysis of the pharynx in an 
adult H, contortus  whereas complete paralysis (defined as loss of motility) requires a 
concentration of  ≥ 10nM IVM (Geary et al. 1993), studies in larval H. contortus and 
in C. elegans show similar effective concentrations (Kass et al. 1980; Avery et al. 
1990; Arena et al. 1995).  But even at these concentrations the head and tail can still 
move and paralysis is contained to the mid section (Geary et al. 1993). It has been 
noted that the different effects of the AMs differ between nematodes and even life 
stages within these nematodes (Gill et al. 1998). In the filarial nematodes AMs are 
highly effective at killing the larval stages but fail to kill the adults, although they still 
suppress fecundity in the adult (Awadzi et al. 1985; Lok et al. 1995). This effect on 
fecundity has also been described in adult H. contortus and C. elegans (Le Jambre 
et al. 1995; Grant 2000). The failure of the AMs to kill adult filarial nematodes has 





1.2.4.2 Human antiparasitic chemotherapy 
 
 
Avermectins were introduced into human medicine in the 1980s. As for animals the 
avermectins are primarily used to fight parasitic nematode infections such as O. 
volvulus. Merck, the company who discovered the avermectins and produced 
ivermectin, donated it to 30 countries in Africa and Central and South America in 
order to combat river blindness and other debilitating parasitic diseases. Annually 
more than 25 million people are treated with a single dose of ivermectin which acts 
to clear any young nematodes of all types out of the system and halting the life cycle. 
In some species, particularly the filaria, the most important effect on the adult worm 
is to suppress new microfilariae production; similar effects on fecundity are seen in 
H. contortus and C. elegans (Vercruysse et al. 2002).   
 
Recently new non anthelmintic applications for the avermectins in human medicine 
have been discovered. For example some avermectins create a modification of the 
sensitivity of Hep-2 and P388 tumour cells to taxol and vincristine, substrates of 
multidrug resistance proteins (Korystov et al. 2004). This property of the naturally 
occurring avermectins can be used in tumour therapy by combining application of 
avermectins with anti-tumour preparations. Interestingly it is the synthetic derivatives 
of the avermectins that are least effective (Korystov et al. 2004). 
 
 
1.2.4.3 Avermectin Resistance  
 
The avermectins are extremely profitable drugs, but over the past few years an 
increasing number of instances of resistance have been reported.  
Ivermectin resistance involving Haemonchus species has been reported by several 
authors in the southern hemisphere, and is becoming a serious threat to the sheep 
industry (J.A. Van Wyk et al. 1997 ).  Cases have also been reported from the 
northern hemisphere in Teladorsagia circumcincta and H. contortus (Jackson et al. 
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1992; Maingi et al. 1996; Yue et al. 2003; Schnyder et al. 2005). It appears that the 
most important issue in the rate at which resistance emerges is the number of worms 
that are left untreated (J.A. Van Wyk et al. 1997 ).  
At the moment current literature is unclear on the basis of resistance to the 
avermectins. There is still some debate on the role of GluCls in avermectin 
resistance with P-glycoproteins also being implicated. Some P-glycoproteins and 
multidrug resistance proteins act as membrane transporters which pump drugs from 
the cell. It has been suggested that a disruption of the mdrla gene, which encodes a 
P-glycoprotein in some species of dog, especially the collie, results in 
hypersensitivity to ivermectin. Genes encoding members of the P-glycoprotein family 
are known to exist in nematodes but the involvement of P-glycoprotein in nematode 
ivermectin-resistance has not been described. Some data suggests that a P-
glycoprotein may play a role in ivermectin resistance in H. contortus, C. oncophora 
and other nematodes  (Blackhall et al. 1998; Xu et al. 1998; Molento et al. 1999; 
Sangster et al. 1999; Prichard R et al. 2007). 
It is clear that avermectins can interact with a variety of different channels in addition 
to the GluCls, including nematode and mammalian GABAA and glycine receptors 
(Adelsberger 2000; Dawson 2000; Shan 2001), α7 nicotinic acetylcholine receptors 
and P2X4 receptors (Krause 1998; Khakh 1999). Therefore, if the GluCls are not the 
only target of the avermectins and milbemycins it is possible that they are also not 
the only source of resistance. 
 
1.3 Cys-loop ligand gated ion channel superfamily  
 
The ligand-gated ion channel (LGIC) superfamily includes the cationic channels 
activated by acetylcholine and 5-HT (Forrester et al. 2003), as well as anionic 
channels activated by GABA, glycine, histamine, and 5-HT (Ranganathan et al. 
2000; Zheng et al. 2002). The overall structure differs from the excitatory glutamate 
receptor family of  vertebrates and they do not respond to the classical glutamate 
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receptor agonists such as kainate, aspartate, or N-methyl-D-aspartic acid (NMDA) 




Figure 10: Tree showing the cys-loop LGIC gene superfamily of C. elegans.  
This figure focuses on cys-loop LGIC subunits other than nAChRs although representative 
subunits of the nAChR groups are shown (Jones et al. 2008) 
 
1.3.1 Nicotinic Acetylcholine Receptors 
 
The primary member of the LGIC family is the nicotinic acetylcholine receptor family. 
The nAChR family is by far the most comprehensively studied and characterised.  
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In nematodes acetylcholine was identified a neurotransmitter in Ascaris and other 
nematodes in 1955 (Mellanby 1955) and was subsequently shown to be an 
excitatory transmitter at nematode neuromuscular junctions (Del Castillo et al. 1963; 
Del Castillo et al. 1964; Del Castillo et al. 1967) 
The model nematode C. elegans has been used as the model organism for 
understanding the nematode  nAChRs and the initial group of C. elegans receptor 
subunits was identified by mutations conferring resistance to levamisole (Lewis et al. 
1980; Fleming et al. 1997). Later studies used genomic sequence analysis to 
elucidate the remaining subunits (Jones et al. 2004). C. elegans has 27 genes 
coding for nAChR subunits; in addition, there are about 20 genes encoding putative 
ionotropic receptor subunits that have not been fully characterized, but could include 
additional nAChR subunits, this is an extraordinarily high number when compared to 
fewer than 20 nAChRs seen in mammals (Rand 2007). 
Five classes of protein subunits have been identified, based on sequence similarity- 
UNC-29, UNC-38, ACR-8, ACR-16, and DEG-3 (Mongan et al. 1998; Mongan et al. 
2002; Jones et al. 2004). Each class contains between three and nine subunits, and 
some of the classes contain both α and non-α type subunits. The UNC-38 class 
contains three α subunits, and is the most homologous to those found in insects. The 
ACR-16 class consists of nine members (α and non-α), and its members resemble 
vertebrate α7 subunits The UNC-29 class contains four non-α subunits; these 
proteins are similar to vertebrate skeletal muscle non-α and insect non-α subunits. 
The ACR-8 class is α nematode specific grouping, and contains three α subunits. 
The DEG-3 class is also nematode specific, and consists of eight verified α and non-
α subunits. The best characterized C. elegans AChRs, based on electrophysiological 
recording and reconstitution in heterologous systems, are at neuromuscular 
junctions (Rand 2007). The muscles of the body wall express two major types of 
ACh receptors: one type responds to levamisole and the other type to nicotine, but 
not levamisole (Richmond et al. 1999). The levamisole-sensitive receptors on the 
body muscles appear to be heteromeric, and contain three essential subunits: UNC-
29, UNC-38, and UNC-63 (Fleming et al. 1997; Richmond et al. 1999; Culetto et al. 
2004). LEV-1 and LEV-8 are also subunits, but they are either non-essential for the 
response to levamisole, or else they are only present in a subset of the receptors 
(Fleming et al. 1997). The nicotine-sensitive receptors appear to be homomeric, 
containing only the ACR-16 α subunit (Francis et al. 2005; Touroutine et al. 2005). 
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Characterisation of the nAChR subunits of the parasitic nematodes has only been 
undertaken in the last few years, with the publishing of the first parasite genomes. 
The major noticeable fact is that the number of nAChR subunits in the parasites is 
far lower than in C. elegans. Brugia malayi has nine subunits and Trichinella spiralis 
just eight (Williamson et al. 2007). This calls in to question the validity of C. elegans 
as a model nematode for nAChR receptors.  
 
Prior to the structural data becoming available invaluable data on the properties of 
nAChRs were gathered by the site directed mutagenesis of individual amino acid 
residues, and the resultant changes in electrophysiological data helped determine 
the gating, ligand-binding, and cation-conduction properties of the ACh.  (Giraudat et 
al. 1986; Akabas et al. 1994; Labarca et al. 1995; Zhong et al. 1998; Grosman et al. 
2000)   Subsequent similar experiments, performed on GABAA, glycine, 5-HT3 and 
neuronal α7 receptors constitute a wealth of complementary information. 
 
1.3.1.1 Nicotinic Acetylcholine Receptor structure 
 
 
Our understanding of the structure of the ligand gated channels is still far from 
complete, but great headway has been made in understanding the structure of the 
primary family member: the nicotinic acetylcholine receptor. Understanding this 
structure is essential for creating a template for understanding the conserved regions 
in the ligand gated chloride channels 
The extra-cellular portion of the each of the receptor subunits contains the ligand 
binding domains and is the most variable and characteristic portion of the nAChR 
subunit. The structure of the N –terminal domain was deduced after the discovery 
and subsequent crystallization of the closely related soluble protein, Acetylcholine 
binding protein (AChBP) from the giant pond snail Lymnaea stagnalis (Brejc et al. 
2001). A series of  β- strands form two β-sheets which fold  tightly to form a  β-
sandwich held together by the characteristic disulphide bridge which forms the Cys 
loop, (Brejc et al. 2001) In the well characterized Torpedo pentamer the ACh-binding 
sites lie at  the interface between  α–γ and α–δ subunits, and are dominated by 
interactions on the α subunits between loops A, B and C, which form the strands 
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connecting β-strands and 6-7, 7-8 and 9-10 respectively  (Corringer et al. 2000; Sine 
2002; Celie et al. 2004).  The intracellular domain of the channel is the smallest part 
and each subunit contributes one α- helix (part of the M3–M4 loop) which form 
together to create a cone shaped “vestibule” (Miyazawa et al. 1999; Unwin 2003) 
See Figure 11. 
The membrane spanning domain of the subunit consists of four α-helices M1–M4 
(Miyazawa et al. 2003). The M2 regions of each subunit shape and line the pore, the 
other helices (M1, M3 and M4), coil around each other to create a shield for the inner 
ring from the lipids. When the channel is closed the M2 helices close and wind 
together in the middle of the pore space creating a hydrophobic barrier known as a 
“hydrophobic girdle” tight enough to prevent ion movement (Beckstein et al. 2004; 
Corry 2004) and it is thought that the opening of this hydrophobic barrier constitutes 
the gating mechanism of the channel itself (Miyazawa et al. 2003; Unwin 2003).  
 
 
Figure 11: Ribbon diagrams of the nACh receptor  
As viewed (a) from the synaptic cleft and (b) parallel with the membrane plane. For clarity, only the 
ligand-binding domain is highlighted in (a) and only the front two subunits are highlighted in (b), the MIR 
and the membrane (horizontal bars; E, extracellular; I, intracellular). The dotted lines on the right denote 




Experiments using electron microscopy carried out on cultured Torpedo postsynaptic 
membranes have helped to determine the structure of this channel and how the 
structure changes upon activation, (Brisson et al. 1984; Toyoshima et al. 1990). 
These experiments used a rapid spray-freezing technique to mimic the synaptic 
release of ACh and trap the open-channel form. (Unwin 1995) These experiments 
showed that binding of ACh initiates two interconnected events in the ligand-binding 
domain.  
The first is a local disturbance in the region of the ACh-binding sites, and the second 
a larger-scale conformational change, involving rotational movements predominantly 
in the two α subunits. The inner M2 helices also change their configuration in 
response to ACh, widening the lumen of the pore at the middle of the membrane. 
Higher resolution studies of the extended conformational change (Unwin 2002) and 
of the structure in the membrane suggested a simplified mechanical model for the 
channel opening mechanism: ACh triggers multiple rotations of the inner β-sheets of 
the α subunits and instigates the twisting movement in M2 regions which breaks the 
gate apart (Miyazawa et al. 1999; Miyazawa et al. 2003; Unwin 2005). 
 
1.3.2 GABA receptors  
 
 
The most abundant synapses in the central nervous system of vertebrates are 
inhibitory synapses that use the L-glutamine derived neurotransmitter, γ-
aminobutyric acid (GABA). GABA was first discovered in 1950 (Awapara 1950; 
Awapara et al. 1950; Roberts et al. 1950). The electrophysiological studies that 
followed over the next two decades discovered the role of GABA as a 
neurotransmitter in the mammalian CNS. Over the years three classes of GABA 
receptors have been identified GABAA, GABAB and GABAC (Schofield et al. 1987). In 
nematodes the observation of fast hyperpolarisation of muscle on the addition of 
GABA pointed to the presence of GABA gated ion channels that were chloride 
dependent but the pharmacological profile of the nematode GABA-mediated 
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response indicates that it is not directly analogous to either the mammalian GABAA 
or GABAB receptors (Hewitt et al.1986), although nematodes do have distinct GABA 
receptors that are similar to vertebrate GABAA or GABAB based on sequence identity 
alone. GABA is also an important neurotransmitter in C. elegans; however, in 
contrast to vertebrates where GABA acts at synapses of the CNS, in nematodes 
GABA acts primarily at the neuromuscular junction (Olsen et al. 1999). GABA acts to 
relax the body muscles during locomotion and foraging and to contract the enteric 
muscles during defecation, this was discovered after observation of mutants with 
GABAergic transmission defects, which although viable, have several severe motor 
defects. The most obvious phenotype is “shrinker” whereby the nematode has a 
tendency to contract dorsal and ventral body wall muscle simultaneously in response 
to touch. This is thought to be as a result of a lack of function of the GABA-




In C. elegans the unc-49 gene encodes three distinct GABAA receptor subunits by 
splicing a common N-terminal ligand-binding domain to one of three alternative C-
terminal domains, producing the UNC-49A, UNC-49B, and UNC-49C subunits 
(Bamber et al. 1999). This gene structure is conserved throughout the phylum and 
has also been demonstrated in C. briggsae. The UNC-49B and UNC-49C subunits 
are expressed in the muscles and localized to synapses from the D-type GABA 
motor neurons (Bamber et al. 1999; Gally et al. 2003; Bamber et al. 2005) The 
GABA receptor localised at neuromuscular junctions is a heteromer composed of the 
B and C subunits (Bamber et al. 2005). The B subunit has been proven to be 
required for localization of the receptor to neuromuscular junctions and the C subunit 
imparts specific pharmacological properties to the heteromeric receptor (Bamber et 
al. 2003; Bamber et al. 2005). The UNC-49A subunit is barely detectable in vivo, and 
is not found co-localised with UNC-49B or UNC-49C to form a functional receptor in 





1.3.3 Glutamate-gated chloride channels 
 
 
The first two glutamate gated chloride channel subunits were discovered by Merck in 
the early 1990’s by isolating mRNAs which elicited an electrophysiological response 
to IVM-P04 and glutamate when injected into Xenopus oocytes (Arena et al. 1992). 
The mRNA fragments were  then cloned to cDNA (Cully et al. 1994). These subunits 
were named GluClα and GluClβ and identified as members of the LGIC superfamily 
from sequence and functional identity with other family members, including the long 
extracellular domain followed by four transmembrane domains. Throughout the 
family there is a high degree of amino-acid sequence similarity, and there are some 
highly characteristic sequence motifs, for example, a 15-residue cys-loop’ that is in 
the N-terminus domain of all members of the family including the GluCls. All the 
subunits form oligomers, and all of these are pentameric, there is also a great deal of 
similarity between the individual subunits that make up each different receptor 
(Ortells et al. 1995). The volume of data that was available on other LGIC family 
members gave valuable insight into the properties of the GluCls from an early stage. 
For example the long intracellular loop between TM3 and TM4 has conserved areas 
with homology to certain protein kinase sequence, which in other family members 
has been shown to effect channel kinetics, channel function and downstream 
signaling (Porter et al. 1990; Wafford et al. 1992; Wafford et al. 1992; Leidenheimer 
et al. 1993; Krishek et al. 1994; McDonald et al. 1994; Macdonald 1995; Moss et al. 
1996; McDonald et al. 1997; McDonald et al. 1998; Filippova et al. 2000; McDonald 
et al. 2001; Song et al. 2005).  
The GluCls also had an additional pair of cysteine residues in the extracellular 
domain, a freature similar to the vertebrate glycine receptor subunits (Cully et al. 
1994). The sequence data shows a great deal of homology to the GABAA and 
glycine receptors of vertebrates although the GluCls do have their own distict group 
within the family (Cully et al. 1996; Vassilatis et al. 1997; Jones et al. 2008).     
GluCls are found only in invertebrates (Cleland 1996) and therefore make good drug 
targets. Ivermectin is a widely used anthelmintic which is known to interact with 
GluCls (Cully et al. 1994; Arena et al. 1995; Cleland 1996; Cully et al. 1996; 
Vassilatis et al. 1997; Dent et al. 2000). Over the last few years several labs have 
concentrated on the cloning and expression of GluCls from C. elegans. These 
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studies have revealed that GluCls are closer in structure to vertebrate GABAA and 
glycine receptors than the expected nAChRs but this not surprising as both GluCls 
and GABAA are anion channels (Cully et al. 1994).  Work done on these isolated C. 
elegans GluCl has concluded that they have a unique pharmacological profile by 
which  channel activation occurs on binding with ligands such as L-glutamate and 
ibotenate (Cully et al. 1994).  
GluCls are extremely sensitive to macrocyclic lactone anthelmintics such as 
ivermectin (IVM) and this interaction contributes to the overall toxic effect of the drug 
in nematodes. Low nanomolar concentrations of IVM potentiate the glutamate 
activation of the chloride channel expressed in Xenopus oocytes whereas 
concentrations in the micromolar range directly activate the channel. IVM channel 
activation is essentially irreversible and this is due to its slow dissociation from the 
binding site (Schaeffer et al. 1989). This results in cellular inhibition and possible 
muscle paralysis of parasitic nematodes, which is likely to contribute to their 
elimination from the host.  
GluCls have been cloned from a variety of species including C. elegans (Schaeffer et 
al. 1989; Cully et al. 1994; Dent et al. 1997; Laughton et al. 1997; Vassilatis et al. 
1997; Dent et al. 2000), Drosophila melanogaster (Cully et al. 1996), and the 
parasitic nematode, Haemonchus contortus (Delany et al. 1998; Forrester et al. 
1999; Jagannathan et al. 1999). However, most of our current knowledge regarding 
the function of GluCls and their interaction with macrocyclic lactones has emerged 
from the expression of cloned channel subunits from C. elegans.  
 
1.3.3.1 Glutamate gated chloride channel pharmacology 
 
GluClα1 and GluClβ were the first GluCls isolated from C. elegans in 1994 (Cully et 
al. 1994) after being discovered as ivermectin sensitive. Analysis of the cDNA 
sequence showed a high level of sequence homology to both glycine and GABAA 
receptor subunits. The GluCls are clearly in the chloride channel branch of the LGIC 
superfamily alongside muscle nAChR. 
 










H. contortus Expression 
pattern 
glc-1 GluCl α1 Unknown - -  
glc-2 GluClβ Pharangeal Muscle (Laughton et al. 1997) Hc Glc-2 (HG4) 
Hc GluClβ 
(HG4) Unknown 
glc-3 GluCl α4 Nerve ring, head muscle1 - -  
glc-4 - 
Intestine; anal depressor 
muscle; head mesodermal cell; 
Nervous system; nerve ring, 
head neurons; tail neurons1  







40 extra-pharangeal neurones 
in the ring ganglia of the head, 
some motor neurons in the 
ventral nerve cord and 
mechanosensory neurons 
(Dent et al. 2000)  
M1 and M4 pharyngeal 
neurones (Franks et al. 2006) 
Hc avr-14 
(gbr-2) 
Hc GluCl α3A 
(Hc GBR-2A) 
 
Hc GluCl α3B 
(Hc GBR-2B) 
Both varients expressed in 
nerve ring, motor neurones 
and amphid neurones 
(Jagannathan et al. 1999; 
Portillo et al. 2003) 
avr-15 GluCl α2A GluCl α2B 
Pharyngeal mucles pm4 and 
pm5. Some head neurones. 
Dorsal and ventralsublateral 
nerve cords. Neurones DA9 
ans VA12 (Dent et al. 1997) 
- -  
- -  Hc GluCl α Hc GluCl α Inhibitory motor neurones(Portillo et al. 2003)  
 
Table 1. Summary of known C. elegans genes, GluCl subunits and expression patterns  and the equivalent 
orthologues in H. contortus. 
1 Unpublished information taken from www.wormbase.org. 
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Table 2. Summary of the pharmacological properties of known C. elegans channels.  








KD IVM (or 
IVMPO4) 
Hill coeff.   
IVM 
Reference 
C. elegans  
mRNA - 300 μM 1.7 90 nM 1.1 
(Arena et al. 1991; Arena 
et al. 1992) 
C. elegans 
pharynx - 166 μM No data 2.7 nM - (Pemberton et al. 2001) 
Ce GluClα1 glc-1 No Response - 140 nM 1.5 (Cully et al. 1994) 
Ce GluClβ glc-2 380 μM 1.9 - - (Cully et al. 1994) 
Ce GluClα1 β - 1.36 mM 1.7 190 nM 2.5 (Cully et al. 1994) 
Ce GluClα 2A avr-15 2.0 mM 1.5 - - (Dent et al. 1997) 
Ce GluClα 2B avr-15 208.3 μM 2.1 108 nM 1.6 (Laughton et al. 1997; Vassilatis et al. 1997) 
Ce GluClα 2Bβ - 62 μM 2.4 103 nM 1.85 (Vassilatis et al. 1997) 
Ce GluClα 3A avr-14 / gbr-2 No Response - - - (Dent et al. 2000) 
Ce GluClα 3B avr-14 / gbr-2 Response at 10 mM - - - (Dent et al. 2000) 
Ce GluClα 4 





Table 3. Summary of the pharmacological properties of known parasitic nematode channels expressed in either 
Xenopus oocytes or COS-7 cells 
EC50  and Hill slope values are expressed as mean ± SEM 
GluCl Subunit GluCl gene EC50 Glutamate 
Hill coeff. 
Glutamate 
KD IVM (or 
IVMPO4) 
Hill coeff.   
IVM Reference 
Hc CluCl α  
(HG5) 
HcGluClα 
 8.4 μM 2.13 131 nM 1.15 (Forrester et al. 2003) 
Hc GluClβ  
(HG4) 
Hcglc-2  /HG4
 - - 
No IVM 
binding - (Cheeseman et al. 2001) 
HcGluClα3A   
(Hc-GBR-2A) (HG2) 
Hc avr-14 
/gbr-2- - - 
No IVM 




gbr-2 unknown unknown 70pM - (Cheeseman et al. 2001) 
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Our current understanding of GluCl pharmacology has been elucidated from several 
experimental approaches, the most important has been two-electrode voltage clamp 
recordings taken from Xenopus oocytes expressing GluCls or tissue preparations 
and radioligand binding studies on either nematode membrane or membrane taken 
from cultured cell lines expressing GluCls.  Obtaining pharmacological data using 
ivermectin has over the years proven difficult due to its viscous consistency and 
highly hydrophobic nature. As a result many data was derived from experiments 
using Ivermectin-phosphate (IVMPO4) a far more soluble compound.  
In C. elegans there are six GluCl genes, at least two of which are alternatively 
spliced giving at least eight functional subunits (Yates et al. 2003). The avr-15 and 
avr-14 genes are alternatively spliced to create two subunits each (Cully et al. 1994; 
Dent et al. 1997; Laughton et al. 1997; Vassilatis et al. 1997; Horoszok et al. 2001). 
Homologues for one of these alternatively spliced genes (avr-14) were also found in 
Haemonchus contortus (see table i) along with GluClβ (Cheeseman et al. 2001).  
GluClα1a and GluClβ  were the first subunits to be isolated and characterised by 
expression in oocytes (Cully et al. 1994).  Oocytes expressing both subunits gave 
electrophysiological responses to both glutamate and IVMPO4, which was 
comparable to earlier studies in which C. elegans mRNA was injected directly into 
oocytes (Arena et al. 1991; Arena et al. 1992). The responses showed a classic fully 
reversible inward chloride current on addition of glutamate; this was blocked on the 
addition of 100 μM picrotoxin (PTX) the chloride channel blocker by 68%. (Cully et al. 
1994) 100μM PTX also blocked the inward currents of the channels activated by 
1μM IVMP04 by 61% (Cully et al. 1994). This blocking action was also repeated with 
the addition of flufenamic acid in similar concentrations used to the same effect in 
the oocytes injected with C. elegans mRNA (Arena et al. 1992). The GluClα1β 
heteromers were also activated by the structural analogue of glutamate:  ibotenate, 
but were insensitive to NMDA, AMPA, acetylcholine, kainate and muscimol at 1mM 
and GABA, L-aspartate, glycine, histamine, β-alanine and taurine at 10mM (Cully et 
al. 1994; Dent et al. 1997; Vassilatis et al. 1997; Horoszok et al. 2001). 
The GluClα1β heteromers were also activated by the structural analogue of 
glutamate:  ibotenate, but were insensitive to NMDA, AMPA, acetylcholine, kainate 
and muscimol at 1 mM and GABA, L-aspartate, glycine, histamine, β-alanine and 
taurine at 10mM (Cully et al. 1994; Dent et al. 1997; Vassilatis et al. 1997; Horoszok 
et al. 2001).  
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Both of these subunits show the ability to form homomeric channels, with the 
GluClα1 pentamers insensitive to glutamate but responsive to IVMPO4, although, it 
was later demonstrated that the GluClα1 subunits can bind glutamate but cannot 
trigger the gating mechanism (Etter et al. 1996). Conversely the GluClβ pentamers 
are readily activated by the addition of glutamate but insensitive to IVM. Homologues 
to the glc-2 gene (GluClβ) have been found in Cooperia oncophora and 
Haemonchus contortus. (Delany et al. 1998; Cheeseman et al. 2001; Njue et al. 
2004) 
The alternatively spliced C. elegans GluCl α2A and GluCl α2B subunits are also able 
to form homomeric pentamers sensitive to both glutamate and IVM. Prior to splice 
variants being characterized the GluCl α2B subunit (or GluCl α2 as it was known) 
was also shown to co-assemble and form heteromeric channels with GluClβ 
(Vassilatis et al. 1997). This increased its sensitivity to glutamate compared to either 
homomeric pentamers but stopped the weak blocking by PTX shown in the 
homomer (Vassilatis et al. 1997). The glc-3 gene product GluClα4 has been shown 
to form homomeric channels sensitive to glutamate and IVM (Horoszok et al. 2001) 
and are blocked by insect-GABA blockers BIDN and Fipronil but are, interestingly, 
insensitive to the action of PTX (Hosie et al. 1995; Hosie et al. 1995; Rauh et al. 
1997; Hamon et al. 1998; Horoszok et al. 2001). 
Of the two splice variants created by the C. elegans avr-14 gene the GluClα3A when 
expressed alone was found to be neither glutamate nor IVM sensitive, in contrast, 
GluClα3B subunit forms homomeric channels that are both activated by glutamate 
and irreversibly opened by IVM (Dent et al. 2000). Homologues of C. elegans avr-14 
gene have been identified in H. contortus, Haemonchus placei and Difilaria immitis, 
and C. oncophora have shown to form similar splice variants. Avr-14 homologues 
which produce only one subunit (GluClα3) have been discovered in Ascaris suum 
and Onchocerca volvulus (Cully et al. 1996; Jagannathan et al. 1999; Cheeseman et 
al. 2001; Yates et al. 2003; Njue et al. 2004; Njue et al. 2004). 
Another subunit has been found in H. contortus, which doesn’t appear to have an 
obvious homologue in C. elegans,   Hc GluClα which encodes the  Hc GluClα 
subunit forms homomeric channels which are both glutamate gated and to which 
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IVM binds with high affinity. (Forrester et al. 1999; Cheeseman et al. 2001; Forrester 
et al. 2002; Forrester et al. 2003) 
The macrocyclic lactones work potently against all manner of invertebrates and are 
powerful insecticides and acaricides and it may be possible to gain insights into the 
anthelmintic action of these compounds, and of resistance to them, by looking at 
their modes of action and resistance in insects. As the IVM sensitive GluCl subunits 
are thought to be the major target of the anthelmintics it is reasonable to believe that 
mutations in or loss of the invertebrate GluCls may confer resistance to the AMs. 
Several insect LGCC are sensitive to avermectins, including the glutamate- and 
histamine-gated chloride channels (HisCl) (Gisselmann et al. 2002; Zheng et al. 
2002). Mutations in the ort gene, encoding one of the HisCl subunits of D. 
melanogaster, alters the susceptibility of the flies to the avermectins (Iovchev et al. 
2002), but specific resistance-associated polymorphisms have yet to be identified in 
this channel. An amino-acid substitution (P299S) in the Drosophila GluClα subunit 
confers a tenfold level of resistance to ivermectin and nodulisporic acid (Kane 2000). 
The affected proline residue is located just after the second transmembrane region 
and is ubiquitous in all known glutamate-, glycine- and GABA-gated chloride 
channels. Homomeric channels were expressed in Xenopus oocytes and two voltage 
clamp electrophysiology carried out to determine the pharmacological effects of the 
mutation. The P299S mutation conferred a tenfold loss of glutamate sensitivity, from 
19.5 μM in the wild type subunits to 201 μM in the P299S DmGluClα subunits. The 
loss of sensitivity to ivermectin was even more marked with a 14 fold loss of 
sensitivity from 25 nM in the wt to 340 nM in the P299S DmGluClα (Kane 2000). 
However, these are laboratory strains and there is no information on the mechanism 
of insect resistance to the ML from the field. 
The GABA-gated chloride channel is the site of action of the cyclodiene insecticides. 
Resistance to these is conferred by a SNP at position 302 of Rdl, a GABA-gated 
chloride channel subunit, with an alanine being replaced with either a serine or a 
glycine (ffrench-Constant RH et al. 1993).  The A302S/A302G substitutions are in 
the important second transmembrane region (M2) of the GABA subunit. Interestingly 
some later expression studies were carried out in Xenopus oocytes have shown that 
the Rdl mutation also results a 3.3 fold decrease in sensitivity to ivermectin (Kane 
2000), and it has been reported that the GluCl and Rdl subunits can be co-
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immunoprecipitated, suggesting that either the GABA and glutamate-gated channels 
are part of the same complex or that Rdl and GluClα co-assemble into a functional 
receptor (Ludmerer et al. 2002): other workers have found that the insect glutamate- 
and GABA-gated channels co-exist and function separately (Zhao et al. 2004). Very 
recently, Eguchi et al. (2006) have found that the Musca domestica GluClα assists in 
the expression of Rdl when the two are co-expressed in the same Xenopus oocyte. 
It is worth noting that the Drosophila mutations that confer resistance to ivermectin in 
both GABA receptors and GluCls are in, or very close to, M2, the membrane-
spanning region that lines the pore and undergoes a conformational change to open 
the channel. This could highlight this part of the receptor as a potential ‘hotspot’ for 
resistance-associated polymorphisms. In nematodes, we have most information 
about the free-living species, C. elegans. Ivermectin kills C. elegans at therapeutic 
concentrations making it a suitable model system to investigate the mechanism of 
resistance and consequently ML resistance has been extensively studied in this 
species. There are a large number of C. elegans genes predicted to encode proteins 
with homology to LGCC subunits and there has been very little work done to date to 
examine the role many of these receptors may play in avermectin sensitivity and 
resistance. Nonetheless, several genes have been found that contribute to IVM 
resistance, however Dent et al. (2000) concluded that the GluCls are the 
physiologically relevant mediators of ivermectin toxicity.  
 
Ivermectin activates GluCl channels that contain α-type subunits; such as the avr-14, 
avr-15,  glc-1 and glc-3 gene products that all individually form ivermectin-sensitive 
channels as described above (Cully 1994; Dent et al. 1997; Vassilatis et al. 1997; 
Dent et al. 2000; Horoszok 2001), and so these are obvious candidate resistance-
associated genes.  Functionally null mutations in any one of the avr-14, avr-15 and 
glc-1 genes do not lead to significantly resistant worms, however a triple GluCl 
mutant displays high level resistance of > 4, 000 fold (Dent et al. 2000); double 
mutants in any two of the genes lead to an intermediate level of resistance. Even in 
the model nematode, this may reflect the necessity for changes in multiple genes to 
cause high-level target-site mediated ML resistance. Other C. elegans gene products 
may interact with the GluCls to mediate ML sensitivity: in particular gap junctions, 
which are composed of the innexins, may allow the drug-induced hyperpolarisation 
to spread to other cells. In the absence of the innexins (UNC-7 and UNC-9 in C. 
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elegans) ML toxicity might be restricted to only those cells expressing GluCl, 
preventing systemic effects (Dent et al. 2000). Both unc-7 and unc-9 genes 
contribute to ivermectin sensitivity, but neither bind ivermectin directly. An additional 
pathway for resistance in C. elegans is controlled by genes that mediate cuticle 
permeability. The dye-filling (dyf) mutants are unable to take up fluorescent dyes 
from the environment through the amphids. When the Dyf gene osm-1 is mutated, all 
genetic backgrounds show reduced effects of ivermectin, presumably due to lower 
uptake of the drug (Dent et al. 2000). The GluCl and the Dyf genes can also act 
together, as the avr-15; osm-1 double mutant is significantly more resistant than the 
osm-1 single mutant though the avr-14; osm-1 mutant is not.   
 
In reality, the big deletions or insertions causing the above artificial mutations are 
relatively unlikely to occur in vivo in comparison to coding single nucleotide 
polymorphisms (SNPs) are the most likely to occur. Coding SNPs that result in 
changes to the tertiary structure which, in turn cause changes to the ligand or drug 
binding site, may cause defect in trafficking and channel assembly. This may also 
reduce the number of effective target sites. Alternatively changes to the tertiary 
structure of the pore lining transmembrane regions could lead to the inability of the 
channel to fully open or close, even with successful ligand binding. Although 
traditionally dismissed, non-coding SNPs can have recently been proven to cause 
the alteration of splice sites and reduction in mRNA stability. Non- coding SNPs may 
be detectable in cDNA, but not obvious. They can cause changes in expression level 
or pattern (perhaps less likely) due to promoter/enhancer polymorphisms. Due to 
their non-coding nature these SNPs would not be detectable in cDNA (Kimchi-
Sarfaty et al. 2007). Larger deletions, insertions, transposable elements etc are likely 
to cause major changes in gene expression as seen in the previously discussed C. 
elegans studies 
In nematodes single nucleotide polymorphisms in targets show dramatic effects on 
the efficacy of drugs, for example the β-tubulin codon 200 TTC/TAC (F200Y) SNP in 
many nematode species that confers high level resistance to benzimidazole, it is 
logical to predict that a similar mechanism may be at work in macrocyclic lactone 
resistance. There have been several reported cases of SNPs in various nematodes 
that confer limited levels of resistance. 
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It is suggested that polymorphisms in the GluCl subunits can confer resistance in 
parasitic nematodes.  A Canadian group cloned two full-length glutamate-gated 
chloride channel (GluCl) cDNAs, encoding GluClα3 from Cooperia oncophora, the 
subunit which is homologous to the C. elegans and H. contortus GluCl α3B channel 
subunit, from ivermectin-susceptible (IVS) and -resistant (IVR) C. oncophora adult 
worms. The IVS and IVR GluClα3B subunits differed at three amino acid positions, 
E114G V235A and L256F all of these SNPs were located in the N terminal domain of 
the C. oncophora GluClα3 subunit, the ligand binding site area, although it is 
important to note the actual ivermectin/ moxidectin binding sites are still unknown 
(Njue et al. 2004), but are thought to be in the transmembrane regions due to the 
hydrophobic nature of the macrocyclic lactone drugs. 
The subunits carrying the candidate SNPs were cloned and expressed in Xenopus 
laevis oocytes. Electrophysiological whole-cell voltage-clamp recordings showed that 
the L256F mutation in the GluClα3 was the only one that caused a small but 
significant threefold loss of sensitivity to glutamate from an EC50 of 29.7± 4 μM to 
100.6 ± 0.21 μM. The efficacy of the macrocyclic lactones ivermectin and moxidectin 
were also significantly reduced with this mutation with the EC50 increasing from 0.5 ± 
0.12 in IVS worms to 1.2 ± 0.11μM in channels carrying the L256F mutation. It is 
also important to note that the GluClα3 channels from the Ivermectin resistant 
population had EC50 comparable to those carrying the L256F mutation, 96.1 ± 4.4 μM 
for glutamate and 1.3 ± 0.11 μM for ivermectin/moxidectin (IVR) (Njue et al. 2004). 
Whether this mutation alone is enough to confer resistance of the nematodes to the 












1.4 Aim of Project 
 
 
Few studies have actually examined the molecular nature of macrocyclic lactone 
action in organisms such as parasitic nematodes (Cheeseman et al. 2001; Forrester 
et al. 2002) which is suprising considering the worldwide expenditure on 
anthelmintics and the emergence of resistance.  
The aim of my project was to characterise the H. contortus GluClα3B subunit, and, 
investigate candidate polymorphisms found in field isolates of IVR nematodes and 
insects  to determine whether they confer resistance, and thus to gain understanding 
of the interactions between the GluCls and their agonists. 
The first stage of the project was to characterise the wt H. contortus GluClα3B 
subunit. This particular subunit was chosen because it had been implicated in IVM 
resistance in C. oncophora  (Njue et al. 2004), and had already been proven to form 
homomeric channels when expressed in Xenopus oocytes that elicit a robust inward 
current that is reproducible in response to glutamate and is also sensitive to IVM.   
The second stage of the project was to investigate GluClα3B-agonist interactions 
further by introducing mutations into the channel. IVR associated SNPs were 
introduced into the IVS GluClα3B. The mutations that were introduced had largely 
been implicated in IVM resistance, including SNPs found exclusively in the GluClα3 
subunit of isolates of  IVR C. oncophora (Njue et al. 2004), the GABAA  and Dm 
GluClα of IVR Drosophila melanogaster (ffrench-Constant et al. 1993; Kane et al. 
2000) and SNPs found in populations of IVR H. contortus (Jagannathan 1998). The 
position of the mutations were visualised using molecular modelling to create a 
homology model of the N-terminal domain of the GluClα3B subunit which would aid 







Chapter 2: Methods and materials 
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2.1 Materials  
 
 
2.1.1 Molecular biology reagents 
 
 
Molecular biology grade chemicals and kits were purchased from Sigma chemical 
company Ltd, (Dorset, UK), PAA laboratories (Somerset, UK), Promega  or Fisher 
scientific (Leicestershire, UK), Ambion (Texas, USA) or promega (Hampshire, UK) 
  
 





50x TAE 2 M tris-acetate, 50 mM EDTA; pH 8.0 
10x TBE 1 M Tris, 0.9 M Boric Acid, and 0.01 M EDTA; pH 8.0 
PBS 140 mM NaCl, 2.7 mM KCl, 10mM Na2HPO4, 1.76 mM KH2PO4;     pH 7.4   
TE 10 mM Tris-Cl, 1mM EDTA; pH 7.6 
10x MOPS 
(500ml) 
20.9 g MOPS in 350 ml DEPC H20, 10 ml 1 M sodium acetate, 10 ml 
EDTA adjusted to 500 ml with DEPC H20. filter sterilised  
6x loading buffer 12 ml H2O, 10ml 0.05M EDTA, 0.05 g Bromophenol Blue, 0.05 g Xylene cyanol 










2.1.1.3 Composition of culture media and buffer  
 
 
Buffer/ solutions Components/ L 
Luria Broth (LB) 25 g Luria broth powder (or 10g tryptone, 10g NaCl, and 5g yeast extract). Autoclaved 
LB Agar 25 g Luria broth powder and 15 g BactoAgar. Autoclaved 
DYT Broth 16g tryptone, 10g NaCl, and 5g yeast extract. Autoclaved 
NZY+ Broth 
10g casein hydrolysate, 5g NaCl, and 5g yeast extract. Autoclaved  
Supplemented before use with 12.5ml 1 M  MgCl2, 12.5 ml 1 M 
MgSO4, 10 ml  2 M glucose   








All buffer constituents and drugs were supplied by Sigma. 
 
Buffer/ solutions Components 
Collagenase Collagenase IA 75mg in 50ml OR-2, filter sterilised. 
Frog Ringer 100.0 mM NaCl,  1.0mM MgCl2,   1.8 mM CaCl2, 2.0mM KCl, 5.0 mM HEPES pH adjusted to 7.5 with NaOH 
ND-96 complete  
96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, 
pH adjusted to 7.5 with NaOH. To 500ml, add 0.5ml 2.5M sodium 
pyruvate and 5ml heat inactivated, dialysed (vs ND96 inc. 1x) FBS. 
Filter sterilise 
OR-2 
82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, pH adjusted 





2.1.1.5 Bacterial strains 
 
 
E coli strain Genotype Supplier 
XL-Blue supE44 hsdR17 recA1 endA1  gyrA46 thi relA1 lac
-
F- [proAB]+ lacIq lacZ ∆M15 Tn10 (tetr0] 
Stratagene Ltd 
Cambridge, UK 
OP50 supE44 hsdR17 recA1 endA1  gyrA46 thi relA1 lac
-
F- [proAB]+ lacIq lacZ ∆M15 Tn10] Stratagene 
JM110 
rpsL (Strr) thr leu thi-1 lacY galK gal Tara tonA tsx 









Enzyme Buffer components (1X) 
T4 DNA ligase 30 mM Tris-HCl, pH 7.8; 10 mM MgCl2, 10 mM DTT, 1mM ATP  
BamH I Buffer E: 6 mM Tris-HCl, pH 7.5; 6 mM MgCl2, 100 mM NaCl, 1 mM DTT 
EcoR I Buffer H: 90 mM Tris-HCl, pH 7.5, 10 mM MgCl2  50 mM NaCl 
Not I Buffer D: 6 mM Tris-HCl, pH 7.9; 6 mM MgCl2, 150 mM NaCl, 1 mM DTT 
Pst I Buffer H: see above  
Sal I Buffer D: see above  
Xba I Buffer H: see above  






2.1.1.7 Antibiotic solutions 
 
 
Antibiotic Stock concentration Working concentration 
Ampicillin 50 mg/ml in ddH2O 50 μg/ml 
Kanamycin 50 mg/ml in ddH2O 50 μg/ml 
 
 
2.1.1.8 Mammalian cell-culture reagents  
 
 
COS-7 (African green monkey kidney cells) were supplied by the European 
Collection of Cell Cultures (Sailsbury, UK). Cells were maintained in Dulbecco’s 
Modified Eagles Medium (DMEM) (Sigma) supplemented with 10% (w/v) Foetal 
Bovine Serum, 2mM L-glutamine, 100,000 units/ 500 ml penicillin and 100mg/ 500ml 
streptomycin (all from PAA). Trypsin EDTA was supplied by Sigma. 
 
 
2.1.1.9 Radioligand binding 
 
Coomassie Plus protein assay Reagent kit supplied by Pierce (Rockford, USA). [3H] 
ivermectin (specific activity 1.44 TBq/mmol) was custom synthesised by Amersham 
International (Bucks., UK) and was a gift from Pfizer Animal Health (Sandwich, UK). 






2.2 Basic Methods 
 
2.2.1 Agarose gel electrophoresis  
 
Agarose gels were made by the addition of 1% (w/v) agarose to 1x TAE or 1x TBE. 
The agarose was dissolved by heating for short (10-20 second) bursts in a 
microwave oven. Visualisation of DNA was enabled by the addition of 5 μg/ml 
ethidium bromide to the slightly cooled molten agarose. The gels were formed by 
pouring the molten agarose into gel rigs and allowed to set. Gels were run in a 
solution of 1x TAE or 1x TBE.   
DNA samples were run after the addition of ~0.25 vol of 6x loading dye. DNA 
molecular weight ladders were also run for estimation of DNA fragment sizes.  
 
2.2.2 Restriction endonuclease digestion of DNA 
 
 
1-5 μg of DNA sample were digested with either 1 or 2 restriction enzymes using a 
two to tenfold excess of enzyme over DNA in the presence of acetylated BSA made 
up in the buffer recommended by the manufacturer for the particular enzyme(s) in 
use.  Reactions were then incubated at the optimal temperature for the enzyme used 





Sterile deionized water  14.5 μl 
RE Buffer 10x   2      μl 
Acetylated BSA 1μg/μl 2      μl  
DNA 1μg/μl   1      μl 
Restriction enzyme 10u/μl 0.5   μl 




2.2.3 Preparation of E. coli competent cells 
 
 
A single colony of E. coli was taken and grown up in 100 ml of LB with shaking for ~ 
3 hours or until it reached OD600. The broth was transferred to an ice-cold 5 ml 
polypropelene tube and cooled on ice for 10 minutes. The broth was centrifuged for 
10 minutes at 2700 x g and 4°C after which the supernatant was discarded and the 
pellet resuspended in 30 ml ice cold 80 mM MgCl2. 20mM CaCl2. The resuspension 
was again centrifuged under the same conditions. The supernatant was discarded 
and the pellet resuspended in 4 ml of ice cold 3 M CaCl2. 
 
2.2.4 Transformation of E. coli cells 
 
Competent cells (300 μL) were mixed with 5μg of plasmid cDNA in pre-chilled 
microfuge tubes and left to incubate on ice for 30-45 minutes. Cells were heat 
shocked at 42°C  for 90 seconds followed by a further 2 minutes on ice. 800μL of LB 
was added and the cells allowed to recover at 37°C for 45 minutes. 200 μL of 
transformed competent cells was then added to LB- ampicillin plates or 5 ml of LB- 
ampicillin medium and incubated at 37°C overnight with shaking.   
 
2.2.5 Small scale preparation of plasmid DNA 
 
  
GenElute™ plasmid miniprep kit (Sigma- Aldrich) was used to isolate plasmid DNA 
from overnight bacterial cultures. 1.5 ml of bacterial broth are harvested via 
centrifugation at 12000 x g for 1 minute, the supernatant discarded and the pellet 
resuspended in 200 μl resuspension solution. This is then subjected to a modified 
alkaline-SDS lysis by addition of 200 μl of lysis buffer for 5 minutes. The lysis is 
halted by the addition of 350 μl neutralization buffer. The protein and bacterial debris 
are removed by centrifugation at 12000 x g for 10 minutes. The supernatant is added 
to a spin column and centrifuged at 12000 x g for 1 minute for the DNA to be 
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adsorbed onto silica in the presence of high salts. Contaminants are then removed 
by a simple wash step of 750 μl wash buffer and 12000 x g for 1 minute. Bound DNA 
is eluted in 100 μl water or Tris-EDTA buffer with a final centrifugation at 12000 x g 
for 1 minute.  
 
2.2.6 Large scale preparation of plasmid DNA 
 
 
GenElute™ HP Plasmid Maxiprep Kit (Sigma-Aldrich) was used to isolate a 100 ml 
overnight recombinant E. coli culture were harvested by centrifugation at 5000x g for 
10 minutes, the supernatant discarded and the cells resuspended in 12 ml of 
resuspension solution using. The cells were then subjected to a modified alkaline-
SDS lysis procedure by the addition of 12 ml lysis buffer for 5 minutes. The lysis was 
halted after addition of 12 ml of neutralization solution and 9 ml of binding solution. 
The lysate is cleared with a filter syringe. The columns were prepared for DNA biding 
by the addition of 12 ml column preparation solution and centrifuged at 3000 x g for 2 
minutes. The eluate was discarded. The filtered solution was passed down the 
prepared centrifuge column and the DNA was bound to the silica-based membrane 
at 3000 x g for 2 minutes, the eluate was discarded and the centrifugation repeated. 
The remaining contaminants were removed by two wash steps; the wash solution 
was added to the column and centrifuged for 3000 x g for 2 minutes, the eluate is 
discarded, this is repeated with two different wash buffers. Finally, the bound DNA is 
eluted in 3 ml of buffer or water with a final centrifugation of 3000 x g for 5 minutes.  
 
 
2.3 Site-directed mutagenesis of GluClα3B cDNA 
 
2.3.1 DNA linearization and site directed mutagenesis 
 
SNP’s were introduced into the linear cDNA of H. contortus IV susceptible clones 
using oligonucleotide primers containing mutations for single amino acid 
substitutions.  
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Site directed Mutagenesis was carried out using Stratagene QuickChange 
mutagenesis kit (Stratagene, La Jolla, USA). 
 
 2.3.2 Primer design 
 
The oligonucleotide primers were designed individually across the area of sequence 
to be altered with at least 12-15 bp of unchanged sequence either side of the target 
base(s). Both the forward and reverse primers contained the desired mutation, 
annealed to the same sequence on opposite strands of the plasmid and were 
between 25 and 45 bases in length, with a melting temperature (Tm) of ≥78°C.  
 
2.3.3 Mutagenesis reaction  
 
The mutation was introduced via a PCR reaction where the mutation was 
incorporated into the template with each amplification.  
 
A typical reaction mixture contained 
 
5 μl   10× reaction buffer* 
10 ng   dsDNA template 
125 ng  oligonucleotide primer #1 
125 ng  oligonucleotide primer #2 
1 μl   dNTP mix 
H2O   to a final volume of 50 μl 
 
Then  
1 μl of PfuTurbo DNA polymerase (2.5 U/μl) 
 
The Reaction was put into the thermocycler with the following program 
95°C 30 seconds 
95°C  30 seconds 
55°C  1 minute    16 cycles 
68°C  1 minute/kb of plasmid length 
 
Following the temperature cycling the reactions were cooled to 37°C 
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2.3.4 Removal of parental dsDNA 
 
Dpn I restriction enzyme (10 U/μl) was added directly to each amplification reaction 
and then immediately incubated at 37°C for 1 hour to digest the parental (i.e., the 
nonmutated) supercoiled dsDNA. 
 
2.3.5 Transformation of mutated plasmid into supercompetent 
cells 
 
XL1-Blue supercompetent cells were thawed on ice. For each control and sample 
reaction to be transformed, 50 μl of the supercompetent cells were aliquoted a 
prechilled 15-ml polypropylene round-bottom tube. 
1 μl of the Dpn I-treated DNA from each control and sample reaction to was added to 
separate aliquots of the supercompetent cells. The transformation reactions were 
mixed gently and incubated on ice for 30 minutes. This was followed with a heat 
shock of 45 seconds in a 42°C water bath and then cooled on ice for 2 minutes. 0.5 
ml of NZY+ broth prewarmed to 42°C was added and the transformation reactions 
were incubated at 37°C for 1 hour with shaking at 225–250 rpm. 250 µl of each 
transformation reaction was plated on large LB–ampicillin agar plates containing 80 
μg/ml X-gal and 20 mM IPTG, and incubated overnight at 37°C.  
 
A number of successfully transformed colonies were picked and grown overnight in 
LB- broth containing ampicillin. The plasmid was then extracted and tested for 




2.4 In vitro transcription of cRNA 
 
2.4.1 DNA linearization  
 
Stocks of pcDNA3.1 vectors containing the HcGluClα3b subunit were linearized 
using Xba I and incubated at 37°C for four hours. The linear DNA was checked on 
an agarose gel. 
DNA was isolated using a phenol: chloroform extraction. The DNA was 5 l reaction 
mixture was added to 205 l nuclease-free H2O and 300 l Phenol: Chloroform: 
Isoamyl alcohol (for DNA, 25:24:1). The mixture was vortexed well and centrifuged at 
5000 x g for 2 min at RT. The upper aqueous layer was retained and 1 vol (~ 300 l) 
chloroform added, Vortexed and centrifuged at 5000 x g for 2 minutes. Again the 
upper layer was kept and 30 l 3M sodium acetate pH 5.2 and 720 μl 100% ethanol 
added, mixed well, precipitated at –20°C overnight. The precipitated DNA was 
centrifuged at 4°C for 15min+ at 5000 x g. The supernatant removed ~200 μl 70% 
ethanol (4°C) added as a wash. The mixture was centrifuged at 4°C for 10min+. The 
pellet was resuspended in 10 μl DEPC or nuclease-free H2O. Quality of DNA was 
checked by running on an agarose gel and measuring absorbance at 260/280 on a 
spectrophotometer.  
 
2.4.2 RNA in vitro transcription 
RNA in vitro transcription was carried out using the mMESSAGE mMACHINE kit, 
(Ambion).  
The following reaction was assembled using RNase free pipette tips and tubes 
3 l    nuclease-free H2O 
10 l   2x NTP/CAP   
2 l 10x Reaction Buffer* 
2 μg linear template DNA   
2 l    enzyme mix† 
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* 10X Reaction Buffer contains 100mM KCl, 100mM (NH4)2SO4, 200mM Tris-HCl 
(pH 8.8), 20mM MgSO4, 1% Triton X-100 and 1mg/ml nuclease-free bovine serum 
albumin (BSA) . 
The reaction was incubated at 37°C for 2hrs for the transcription to occur 1 l DNase 
(2 U/μl) was added and mixed well to destroy the linear template DNA. This was 
incubated at 37°C for a further 15 min. 115 l Nuclease-free H2O and 15 l 
Ammonium Acetate Stop Solution (kit) was added to halt the DNase activity. 
RNA was extracted with 1vol (150 l) phenol: chloroform (5:1 nuclease-free).  The 
upper aqueous layer was retained and further extracted with 1vol (150 μl) chloroform 
(nuclease-free). Again the top layer was retained. 1 vol isopropanol (nuclease-free) 
was added, mixed well and chilled at –20°C overnight. The RNA precipitate was 
centrifuged for 5000 x g at 4°C for 15min. The supernatant was removed and the 
remaining supernatant allowed to evaporate at RT. 
The RNA was re-suspended in 10 L nuclease-free H2O and preferably used fresh 
to inject into oocytes. Alternatively the RNA was aliquoted into 5x 2 L and stored at 
–80°C. 
 
* 10X reaction buffer comes exclusively with Ambion mMESSAGE mMACHINE kit 
and is labelled as containing salts, buffer, dithiothreitol, and other ingredients.   
† Enzyme mix comes exclusively with Ambion mMESSAGE mMACHINE kit and is 
labelled as containing 50% buffered glycerol containing RNA polymerase, RNase 
inhibitor and other components 
 
2.4.3 RNA Reducing gel 
 
RNA reducing gels were prepared by making up a 2% (w/v) agarose gel in a solution 
of 1x MOPS containing 20% formaldehyde (37% w/v). 
 
To 2 l of the RNA samples from the transcription reaction was added: 
 2 l   RNA (or 5 l RNA ladder NEBL),  
2 l  10x MOPS  
4 l   Formaldehyde       
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10 l Formamide  
1 l Ethidium bromide (200 g/ml)  
 
The samples were prepared for running on RNA reducing gel by heating the sample 
mixture containing at 75°C for 10 min then adding loading buffer e.g. 3 l 6x.   
The gel tanks were washed with 3% H2O2 or RNase Away before use. The gels were 
run in 1x MOPS. Photo gel at ½ sec f5.6 
 




2.5.1 Isolation of Xenopus oocytes 
Ovarian tissue was isolated from mature female Xenopus laevis by a simple surgical 
procedure. The frogs were by euthanized by immersion in benzocaine solution 0.2 % 
w/v. The isolated ovarian lobes were placed in a 50 ml centrifuge tube containing 
OR-2 calcium-free buffer and washed three times in fresh buffer using a sterile glass 
Pasteur pipette on an aspirator. The lobes were then placed in a dish and dissected 
into smaller clumps of oocytes. These were rinsed several times in OR-2, and gently 
shaken in OR2 containing 4 mg/ml collagenase type 1A (Sigma) for 75 minutes at 
cool room temperature (20°C). The oocytes were rinsed thoroughly in OR2 before 
being placed incomplete ND96 buffer. The largest oocytes were manually selected 
and allowed to recover overnight in fresh ND-96 with gentle shaking at 18°C.  
 
 
2.5.2 Injection of oocytes  
50nL of cRNA (~1 ng) in RNAse-free water was injected cytoplasmically into each 
oocyte using a micro-injector on a micromanipulator. Injected oocytes were 
maintained at cool room temperature (20°C) in ND96 and electrophysiological 
recordings were performed at room temperature (22 25°C) 2 3 days after injection. 



















Figure 12: overview of the basic processes involved in the production of GluCl 
channels in Xenopus oocytes. 
 
2.5.3 Electrophysiology   
Whole-cell currents were recorded from oocytes using the two-electrode voltage-
clamp technique. Oocytes were voltage-clamped at a holding potential of 80 mV 
and continually superfused with frog ringer. Recording microelectrodes were filled 
with 3 M potassium chloride, and had tip resistances of 0.5-5 MΩ. Oocytes were held 
in a 0.13 ml bath, and continually superfused with frog ringer at a rate of 0.8 ml/min. 
Drugs were applied by superfusion in the same way as the ringer at the same rate, 
the duration of the drug application was 10-20s. For the dose response 
experiments, recordings were made sequentially from the lowest to the highest drug 
concentration, with an interval of 5 min between applications. Glutamate and 
ibotenate was dissolved in frog ringer. Ivermectin was prepared as 10 mM stock 
solutions in dimethyl sulfoxide (DMSO) and again diluted in frog ringer. 
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2.5.4 Electrophysiology data analysis 
 
Data were analysed using Graphpad prism 4 (San Diego, USA). Non linear 
regression analysis was used to fit a sigmoidal dose-response curve of variable 
slope to normalised data using the following equation 
.  
I= Imin + (Imax - Imin)/ 1+10 [log EC50-[ag] H] 
 
Imax and Imin represent the (percentage) maximal and inward current induced by the 
agonist. The EC50 is the concentration of agonist required to elicit half the maximum 
response, H is the Hill slope coefficient and [ag] is the agonist concentration.   
The student’s t-test was used to calculate the whether differences in the EC50 and 
Hill numbers was significantly different. 
 
 
2.6 Expression of GluCl cDNA in mammalian cell lines 
for ligand binding 
 
2.6.1 Maintenance of COS-7 primate kidney fibroblast cells. 
Cells were grown in either 25cm3 or 75 cm3 flasks containing in an appropriate 
volume of supplemented DMEM. The flasks were incubated at 37°C with 5% CO2 . 
The cells were split once they have reached ~ 90% confluence. The cells were 
washed with sterile PBS warmed to 37°C, 1-2 ml of trypsin/EDTA was added and 
cells incubated at 37°C until floating then trypsin activity was inactivated by adding 8-
10 ml fresh pre warmed supplemented DMEM. Cells were split at a ratio 1:8 – 1:10 
into new flasks containing supplemented DMEM. Using this method the cells 
reached confluence in 3-4 days.  
 
2.6.2 Preparation of cells for storage in liquid nitrogen. 
 
Cells were grown in a 75 cm3 flask and, at approximately 80-85% confluence were 
washed with pre warmed PBS, and harvested using  1 ml trypsin/EDTA  until floating 
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and then made up to 10 ml with supplemented DMEM. In a 15 ml sterile centrifuge 
tube the cells were centrifuged at 1500x g for 5 minutes and the supernatant 
discarded. The cells were resuspended in 1ml of freezing medium and transferred 
into cryotubes. The cells were cooled in the gaseous phase of liquid nitrogen for 24h 
before transfer to liquid nitrogen. Alternatively the cells were placed in a 
StrataCooler® Cryo preservation module (Stratagene) which was kept in a -80°C 
freezer overnight to cool the cells at a controlled rate. The cells were transferred to 
liquid nitrogen the following day.        
 
2.6.3 Re-establishment of frozen COS-7 cells 
 
Frozen aliquots of cells were removed from liquid nitrogen and quickly thawed in a 
37°C  water bath and added to a 75 cm3  flask containing pre warmed supplemented 
DMEM. Once the cells had established and adhered to the flask surface, the 
Supplemented DMEM was replaced to get rid of any residual DMSO from the 
freezing medium.    
 
2.6.4 Transfection of COS-7 cells  
 
Lipofectamine™ 2000 was used to transiently transfect COS7 cells. Most 
transfections were carried out in 10 cm3 tissue culture dishes or on coverslips in 6 
well plates. 
 
Complexes were prepared using a DNA (μg) to Lipofectamine™ 2000 (μl) ratio of 1:2 
to 1:3 for most cell lines.  
One day before transfection, dishes were seeded in 12 ml of DMEM supplemented 
with L-glutamine but in the absence of antibiotics so that cells will be 90-95% 
confluent at the time of transfection. 
Plasmid DNA was diluted in 50 μl of Opti-MEM® I Reduced Serum Medium without 
antibiotics. In another non-polypropelene tube Lipofectamine™ 2000 was mixed 
gently with 50 μl of Opti-MEM® I Medium. This was incubated for 5 minutes at room 
temperature. After which the DNA and Lipofectamine™ were combined, mixed 
gently and incubated for 20 minutes at room temperature to allow forming 
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complexes. 100 μl of the complexes were then added to each well containing cells 
and medium and mixed gently by rocking the plate back and forth. Medium was 
changed after 4-6 hours. 
Cells were incubated at 37°C in an incubator with 5 % CO2 for 18-48 hours prior to 




2.6.5 Preparation of membranes from cultured cells 
 
Transiently transfected COS-7 cells were harvested after 48hours in a 100cm3 cell 
culture plate, at this point the cell were usually between 85-90% confluent. 
Control cells were also harvested at ~85% confluence .The culture medium was 
removed by aspiration from the plate and the cells washed three times with room 
temperature 50 mM HEPES with 0.01% (w/v) sodium azide (pH 7.4). Cells were 
harvested with a cell scraper in 5 ml of the 50 mM HEPES with 0.01% (w/v) sodium 
azide and placed in a 15 ml universal centrifuge tube. The cells were further 
disrupted by sonication in 3x 10 second bursts on medium power. 
The medium was made up to 10 ml with more 50mM HEPES with 0.01% sodium 
azide and added to a 10 ml ultracentrifuge tube. The cells were centrifuged at 28,000 
rpm (75,000g) for 30 minutes at 4°C. The supernatant was discarded and the cells 
resuspended in 1 ml 50 mM HEPES with 0.01% (w/v) sodium azide and 0.2 mM 
PMSF.  
 
2.6.6 Measuring protein concentration 
 
The protein was concentration was measured using the Coomassie plus protein 
assay reagent kit (Pierce, Rockford, USA) 
Prior to the first use a standard curve was established using known concentrations of 
protein (bovine serum albumin) supplied with the kit.  
5 μl of each standard or unknown sample was added into the appropriate microplate 
wells.  250 μl of the Coomassie Reagent was added to each well and mixed with 
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plate shaker for 30 seconds. Plates were incubated for 10 minutes at room 
temperature (RT). The absorbance was measured at or near 595 nm with a plate 
reader. The average 595 nm measurements for the Blank replicates were subtracted 
from the 595 nm measurements of all other individual standard and unknown sample 
replicates. A standard curve was prepared by plotting the average Blank-corrected 
595 nm measurement for each BSA standard vs. its concentration in μg/ml. The 
standard curve was used to determine the protein concentration of each unknown 
sample. 
 
10 µl of membrane preparation or 10 µl of blank solution was added to 300 µl of 
Coomassie reagent and mixed on a shaker, incubated for 10 minutes at room 
temperature and then the absorbance was measured at 595 nm with a plate reader. 
The average 595 nm measurement for the Blank replicates was subtracted from the 
595 nm measurements of all sample replicates and the protein concentration 
calculated by reading the absorbance vs. protein concentration of the standard 
curve. 
 
2.6.7 Binding of [3H]-ivermectin to membrane preparations 
 
[3H]-ivermectin binding studies were carried out in 5ml polypropylene tubes. 
Membrane preparations were incubated with [3H]-ivermectin in 50 mM HEPES (pH 
7.4) with 5-40 μg protein (10 μg standard). Non specific binding was determined by 
binding in the presence of 10 μM of unlabeled (cold) ivermectin, the final assay 
volume was made up to 1 ml with 50 mM HEPES. The reactions were incubated at 
room temperature for 2 hours. The binding reaction was terminated by dilution with 
3ml cold wash buffer of HEPES with 0.01% (w/v) sodium azide and 0.25% (v/v) 
Triton X-100. The halted reactions were filtered through type A/B glass fibre filters 
(Whatman, Kent, UK) which had been pre-soaked in 3% (v/v) Polyethyleneimine 
(PEI) in wash buffer. The filters were rinsed 3 times in wash buffer and placed in 
individual mini vials to which 5 ml of Optiphase Safe was added (Wallac, Bucks, UK). 
Bound radioactivity was determined by liquid scintillant spectrometry. 
 
  66
2.6.8 Radioligand binding data analysis 
 
Data were analysed using Graphpad prism 4 (San Diego, USA). Non linear 
regression analysis was used to determine the disassociation constant for the 
equilibrium binding of the radiolabel ligand (Kd) fitted to a single-site binding model. 
Data were fitted to the equation 
 
Y= (Bmax)[[3H] ligand])/ Kd + ([3H] ligand) 
 








2.7 Homology modeling  
 
2.7.1 Template search and selection  
 
A BLAST search (Altschul et al. 1997) through NCBI was used to identify 
homologous structures by searching the structural database of protein sequences in 
the protein data bank (PDB) (Berman et al. 2000). The program modeller 9v2 was 
also used in a parallel study to find the best template. This program searches for 
potentially related sequences of known structure and is performed by the 
profile.build() command of MODELLER. This command initializes the ‘environment’ 
for the modeling run, by creating a new ‘environ’ object then creates a new 
‘sequence_db’ object, calling it ‘sdb’? 'sequence_db' objects are used to contain 
large databases of protein sequences. The program then reads a text format file 
containing non-redundant PDB sequences at 95% sequence identity into the sdb 
database. Sequences which have fewer than 30 or more than 4000 residues are 
discarded, and non-standard residues are removed. A binary machine-specific file is 
written and creates a new 'alignment' object, calling it 'aln'. Profiles contain similar 
information to alignments, but are more compact and better for sequence database 
searching. Searches the sequence database 'sdb' for our query profile 'prf'. Matches 
from the sequence database are added to the profile. Modeller then writes a profile 
of the query sequence and its homologs. The equivalent information is also written 
out in standard alignment format. 
Two searches were compared and the best match decided. The crystal structure of 
the acetyl binding protein from Lymnea stagnalis (PDB code: 1I9BA) was selected as 
a template for the homology modeling for the GluClα3B subunit. 
 
2.7.2 Sequence – template alignment  
The amino acid sequences of GluClα3B and 1I9B were aligned using align2d() 
command in MODELLER, which aligns multiple sequences using a pairwise 
progressive alignment algorithm. The alignments were checked for any deletions or 
insertions in the structurally conserved and structurally variable regions between the 
template and target sequences.  
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2.7.3 Model generation 
 
Homology models of wt and Mutant Gluclα3B were constructed using Modeller 9v2 
(default parameters), based upon the individual sequence/template alignments. 
Modeller  is a comparative modelling methodology which automatically generates a 
3D homology model of a protein sequence based on a given sequence alignment to 
a known 3D protein structure (Sali et al. 1993). Modeller was downloaded from 
http://salilab.org/modeller/download_installation.html.  Modeller was installed and 
used to model 3D structure of protein by satisfaction of spatial restraints on the 
structure of the amino acid sequence. The restraints operate on the distances, 
angles, dihedral angles and pairs of dihedral angles and other spatial features 
defined by atoms. Modeller automatically derives the restraints only from known 
related structures and their alignment with the target sequence. The output is a 3D 
structure that satisfies these restraints as well as possible (Sali et al. 1993) 
All structures and models were visualised using the protein explorer 2.80 
(file:///C:/Program%20Files/Protein_Explorer_2.80/protexpl/frntdoor.htm). 
 
2.7.4 Model Assessment  
 
The stereochemical, volume and surface properties of the models were evaluated 







Chapter 3: Characterising the Molecular 









Previous work carried out in the laboratory isolated five partial cDNAs from H. 
contortus by reverse transcription-polymerase chain reaction (RT-PCR) amplified 
from primers matching highly conserved areas of ligand gated chloride channels 
(Laughton 1993).  Two of the cDNAs were first identified as HG2 and HG3 which are 
actually splice variants of the same gene Hcavr-14 later renamed GluClα3A and 
GluClα3B. It was demonstrated by rapid amplification of cDNA ends (RACE) PCR 
that the avr-14 gene was present in H. contortus eggs (Jagannathan 1998) and that 
the pattern of alternative splicing first identified in the C. elegans avr-14 gene 
(Laughton et al. 1997) was conserved in H. contortus. Similar splice variants of the 
same gene have been found in other species such as Haemonchus placei and D. 
immitis (Jagannathan et al. 1999; Cheeseman et al. 2001; Yates et al. 2004) 
although not in other species such as C. oncophora, A. suum, or Onchocerca 
volvulus (Cully et al. 1996; Njue et al. 2004; Njue et al. 2004). Of the splice variants 
GluClα3A appears was found not to form functional channels when expressed in 
Xenopus oocytes and did not bind to ivermectin when expressed in mammialian cells 
(Cheeseman et al. 2001). The  GluClα3B subunit does bind  ivermectin with high 
affinity (Cheeseman et al. 2001) and produce functional homomeric channels when 
expressed in Xenopus oocytes (Rogers unpublished) which were activated by 
glutamate and irreversibly opened with IVM. GluClα3B has also been implicated in 
IVM resistance in C. oncophora (Njue et al. 2004), indicating that this subunit was an 
important target for IVM and possibly a site of interest in the development of 
anthelmintic resistance, and as a result the decision was made to characterise the 
pharmacology of the subunit more fully. Some preliminary work had already been 
carried out using electrophysiology by Adrian Rogers, a former worker in the lab, he 
had first expressed the GluClα3B subunit in Xenopus oocytes and ascertained that 
the channel was sensitive to Glutamate and irreversibly opened with IVM, that the 
irreversibly opened channel could be blocked with picrotoxin, however further work 
was required to quantify these data.  
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Full length clones of the GluClα3B subunit were translated into mRNA and injected 
into Xenopus oocytes where the subunits were transcribed and assembled into 
functional subunits on which electrophysiological experiments could be carried out.  
The GluClα3B cDNA was also transfected into COS-7 cells and the resultant 






3.2.1 Action of glutamate on oocytes injected with GluClα3B cDNA 
 
 
Full length cDNA encoding the GluClα3B subunit was transcribed by in vitro 
transcription to produce cRNAs that were expressed in Xenopus oocytes. It was 
found that injection of 1 ng cRNA injected was sufficient to produce a robust and 
reliable electrophysiological response up to ~5000nA (The cRNA was produced and 
stored in 2 μl aliquots in thin walled 200 μl PCR tubes at -80°C for no more than two 
months). Recordings were made between 48 hours and 5 days post injection. At a 
holding potential of -80 mV, L-glutamate elicited robust inward currents in all oocytes 
successfully expressing the GluClα3B subunits.  The responses were dose 
dependent with increasing inward currents corresponding to increasing 
concentrations of glutamate and were extremely rapid in onset and reversible (see 
Figure 13) creating a dose response curve generating an EC50 value of 27.6 ± 2.7 
μM. The maximal response for glutamate in IVS GluClα3B channels is at 300 μM 
with 100 μM giving a 95% maximal response. The Hill coefficient of the homomer to 
glutamate is 1.89 ± 0.35 clearly suggesting that more than one molecule of 
glutamate is required to gate the channel. Control oocytes that were either un-
injected or injected with 50 nl ddH20 failed to elicit any response to glutamate at 


































Figure 13: Activation of GluClα3B homomeric channels by glutamate.  
A) Representative current traces from oocytes when activated with glutamate at the concentration 
shown above each trace. Horizontal bars relate to the duration of the glutamate application.  
B) Glutamate dose-response curve for oocytes injected with H. contortus GluClα3B cRNA. Data 
were normalised to the maximum glutamate responses seen with each oocyte, and are shown 








Ibotenate elicited a visually similar electrophysiological response to glutamate 
(Figure 14). Ibotenate is a structural analogue of glutamate known to open GluCls 
(Lea et al. 1973; Arena et al. 1992; Cully et al. 1994) On addition to the GluClα3B 
channel it elicited a response, with kinetics similar to those shown by glutamate. The 
EC50 for glutamate is 27.6 ± 2.7 μM and for ibotenate 87.7 ± 3.5 μM.  At 300 μM 
glutamate shows a maximal response (100%) with ibotenate eliciting a response 69 
± 5.2 % of the maximum See (Figure 14).  The Hill coefficient of the homomer to 
glutamate is 1.89 ± 0.35 indicating cooperativity, this is a trend that is followed with 
ibotenate that has a Hill number of 1.70 ± 0.36, which, although lower than glutamate 
is still indicative of a level of cooperativity.  These data suggest that it is a partial 







































Figure 14: Typical electrophysiological response of GluClα3B homomeric channel to 
ibotenate.  
A) Representative current traces from oocytes when activated with glutamate and ibotenate at the 
concentration shown above each trace. Horizontal bars relate to the duration of agonist 
application.  
B) Ibotenate dose-response curve for oocytes injected with H. contortus GluClα3B cRNA. Data 
were normalised to the maximum glutamate responses seen with each oocyte, and are shown 










The effects of IVM were also tested on the homomeric channel. Unlike the glutamate 
and ibotenate response the effect of IVM was a slow and irreversible activation. The 
current did not return to the baseline even after periods of prolonged washing (>15 
minutes) with drug-free ND96 buffer. Application of 300 μM glutamate after addition 
of maximal response to IVM did not elicit any additional response. No response to 
IVM was observed in either group of control oocytes, one group being un-injected 
the other being injected with 50 nl sterile water.  It was observed that IVM would elicit 
a maximal response, even with the addition of low concentrations, and addition of 
higher concentrations of IVM affected the speed of activation rather than the 
magnitude, with even picomolar concentrations activating a current higher than the 
maximal response to glutamate. This made the production of the IVM standard curve 
laborious and difficult and results in large standard errors. Despite the practical 
difficulties data suggest an EC50 of 0.14 ± 1.01 nM for IVM in oocytes expressing the 

































Figure 15:  Activation of GluClα3B homomers by ivermectin (IVM),  
A) Representative current traces from oocytes when activated with glutamate and IVM at the 
concentration shown above each trace. Horizontal bars relate to the duration of the glutamate 
application.  
B) IVM dose-response curve for oocytes injected with H. contortus GluClα3B cRNA. Data were 
normalised to the maximum glutamate responses seen with each oocyte, and are shown as 
the standard error of the mean of nine oocytes (taken from six individual frogs).  
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Work carried out by Adrian Rogers in the Wolstenholme lab investigated the effect of 
common agonists picrotoxin (PTX) and fipronil. Fipronil was shown to partially but 
irreversibly block glutamate. The channels remained blocked after prolonged periods 
of washing (see Figure 16).  PTX was shown to completely block GluClα3B channels 
with an approximate IC50 of 40 μM (Rogers 2004-unpublished), but the effect is fully 
reversible after washing. In addition PTX acts to partially reverse the effects of IVM 








Figure 16:  Fipronil partially blocks GluClα3B channels irreversibly 
Figure shows a typical Glutamate reaction which is blocked on application with fipronil. 
















Figure 17: Picrotoxin blocks homomeric GluClα3B channels reversibly  
A. Responses to Glutamate, before during and after application with PTX      
B. Typical relative responses of GluCl α3B to ivermectin. There is incomplete reversal of 







3.2.5 Action of [3H]-IVM binding on membrane preparations 




Due to the difficult nature of quantifying IVM standard curves using 
electrophysiology, investigation into the effects of IVM binding on GluClα3B subunits 
with candidate SNPs was carried out using  [3H]-Ivermectin. Previous experiments 
have shown that GluClα3B binds [3H]-IVM with high affinity at a Kd of 70 ± 19 pM in 
COS-7 membrane preparations transiently transfected with the GluClα3B 
(Cheeseman et al. 2001). COS-7 cells were transiently transfected with GluClα3B 
cDNA and membrane preparations taken. Initially binding was determined by 
incubating increasing concentrations of membrane protein 1 μg-50 μg with 0.5 nM 
[3H]-IVM for two hours at 18-22°C. Specific binding appeared to increase in a linear 
fashion with increasing concentration. A concentration of 10 μg protein was decided 
upon for all further experiments because it is a high enough concentration to show 
high levels of specific binding. Non specific binding was determined by incubation 
the presence of unlabelled IVM. No specific binding was seen when the [3H]-IVM 
was incubated with either non-transfected COS-7 membrane preparations, or 
membrane preps transfected with empty pcDNA3.1 vector.  
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3.2.6 Saturation analysis of [3H]-IVM binding to GluClα3B 
 
 
Specific high affinity [3H]-IVM binding was observed to membranes from GluClα3B 
transfected cells. Initial experiments were carried out measure the level of total, 
specific and non specific binding of [3H]-IVM to 10µg of total protein taken from 
GluClα3B transfected COS-7 cells (Figure 18).  Non- specific binding accounted for 
approximately 35-40% of the total binding. 
 
 











Figure 18.  Raw saturation data of 10 µg COS-7 membrane preparations transiently 
expressing IVS wt GluClα3B with [3H]-IVM. 
10 μg of membrane protein was incubated with various concentrations of [3H]-IVM 
for 2 hours at room temperature. Non specific binding was determined in the 
presence of 10μM unlabelled IVM 
The blue curve respresents total [3H]-IVM binding, the red line shows non-specfic 




The raw specific binding data was analysed and the specific [3H]-IVM binding in 
fmol/mg was calculated. The [3H]-IVM binding reached saturation with a Bmax value of 
0.83 ± 0.06 pmol/ mg and kd of 0.35 ± 0.10 nM. Variation in Bmax between 
transfection reactions was not significant. Each reaction was repeated eight times 











































Figure 19: Saturation of COS-7 membrane preparations transiently expressing IVS wt 
GluClα3B with [3H]-IVM.  Inset is the Scatchard plot. 
10 μg of membrane protein was incubated with various concentrations of [3H]-IVM 
for 2 hours at room temperature. Non specific binding was determined in the 











It has been known for several years that GluClα3B subunits form homomeric 
channels when expressed in Xenopus oocytes, the channels are gated by both 
glutamate and ibotenate in a reversible manner and by ivermectin (IVM) which opens 
the channel irreversibly (Cheeseman et al. 2001).  Picrotoxin is a nonselective 
blocker of  GABA that is known to block C. elegans GluClβ and CluClα (Etter et al. 
1999) so it is unsurprising that it has a similar effect in H. contortus. Fipronil is an 
insecticide that also acts on GABA receptors and other closely related channels such 
as the GluCls  (Horoszok et al. 2001). 
 
The H. contortus data is comparable C. elegans data published by Yates et al in 
2003 shows C. elegans GluClα3B has a EC50 2.23 ± 1.2 mM and a Hill coefficient of 
0.72 ± 0.08 in direct comparison to the H. contortus values of 27.6 ± 2.7 μM and Hill 
value of 1.89 ± 0.35. Evidently the H. contortus subunit is far more sensitive to 
glutamate and also displays a level of cooperativity not seen in C. elegans.  Data 
from the C. oncophora GluClα3 subunit was also published in 2004 and showed an 
EC50 to glutamate of 13.4 ± 2.5 μM and a Hill coefficient of 1.9 ± 0.28 (Njue et al. 
2004),  these are similar in magnitude to the H. contortus values. It could be argued 
that the channel sensitivity to glutamate may be parasite specific, although with data 












Figure 20: Comparison Glutamate dose-response curve for oocytes injected with of H. 
contortus (blue) and C. elegans (red) GluClα3B cRNA. 




Species EC50 Glutamate Reference 
H. contortus 28 μM - 
C. elegans 2.2 mM (Yates et al. 2003) 
D. immitis ~ 1 mM (Yates et al. 2004) 
C. oncophora 30 μM (Njue et al. 2004) 
 
Table 4: Summary of GluClα3B subunit sensitivities to glutamate   
 
 
The saturation curve for ivermectin shows a KD  of 0.35 ± 0.10 nM, which is a factor 
of 10 higher than the previous experimentally derived value of 70 ± 6 pM 
(Cheeseman et al. 2001). This may be due relative transformation efficiency of the 
COS-7 cells; both experiments were carried out on 10 µg of transfected membrane 
preparation that contains GluClα3B protein as well as endogenous COS-7 
membrane protein. Higher transformation efficiency would result in proportionally 




















more GluClα3B protein, resulting in more ligand binding per µg protein. In both sets 
of experiments COS-7 cells were used. The batch of cells used in the experiments 
described here were new with fewer than 20 passages, the age of the cells in 
previous experiments is unknown. It is known that the sequence of the GluClα3B 
cDNA was identical in both sets of experiments (excluding introduced mutations) and 
the same pcDNA 3.1 vector was used, ruling out loss of IVM affinity due to unnoticed 
mutations in the sequence. It is also possible that small changes in the activity of the 
radioactive ligand could play a part. that different preparations of [3H]-IVM were 
used.  Differences in the relative activity of different batches of the same radioactive 
ligand have been repeatedly observed over the years and considered a pitfall in an 
otherwise excellent technique (Keen 1995). The batches of [3H]-IVM used in both my 
experiment and in the previous experiments were made by different companies, thus 
opening up the possibility of numerous differences in manufacture that could explain 
the differences in KD. In addition to the manufacturing process, minor changes in 
experimental procedure and simply calculation error could play their part, including 
differences in the efficiency of different scintillation counters. The fact that in both 
cases the SEM is well within an acceptable range indicates that both data sets are 
essentially correct and comparable to other data sets carried out with the same 
reagents under the same conditions, this is further supported by the subsequent 
experiments discussed in the next chapter using mutated versions of the GluClα3B 
subunit.  
 
Comparison of the inward current elicited by the agonists of the GluCl show marked 
differences. The maximal inward current is produced by concentrations of glutamate 
of over 300 μM, but the inward current elicited by the irreversible agonist IVM is  on 
average ~ 170% of the maximal glutamate current. Therefore it could be argued that 
glutamate is only a partial agonist of the homomeric GluClα3B channel and the 
channel only requires a partial opening to be effective. Alternatively glutamate is 
capable of fully opening all channels desensitising is occurring so fast that the 
electrophysiology equipment in incapable of recording the full extent chloride influx. 
Another question raised is whether glutamate is therefore required to be present 
before IVM irreversibly opens the channel. Experimentally, when IVM was applied to 
the oocytes it was only done on the oocytes that had shown positive responses to 
glutamate, therefore had previous exposure to it. This was done because it was the 
  85
only way of telling whether successful production of channels had occurred. The 
oocytes were then washed for 5-10 minutes with frog ringer before application with 
IVM. However we cannot be certain that this was sufficient to wash all the glutamate 
away. One possible mode of action for IVM is the agonist activates the channel and 
then holds it open allowing the influx of chloride ions, another theory might suggest 
that the presence of an agonist at the traditional binding site is required and that IVM 
in its hydrophobic nature is able to gain access to a position between the helices of 
the transmembrane region and “wedge” open the channel. From the data presented 
here it is impossible to say from these experiments whether either is the case.  
   
In order to further characterise the interaction between agonists and the GluClα3B 
subunit, mutations were introduced into the subunit and electrophysiology and ligand 








Chapter 4: Analysis of the effect of Single Amino Acid 








It is suggested that polymorphisms in the GluCl subunits can confer resistance to 
parasitic nematodes.  A Canadian group cloned two full-length glutamate-gated 
chloride channel (GluCl) cDNAs, encoding GluClα3 from Cooperia oncophora, the 
subunit which is homologous to the C. elegans and H. contortus GluClα3B channel 
subunit, from ivermectin-susceptible (IVS) and -resistant (IVR) C. oncophora adult 
worms. The IVS and IVR GluClα3B subunits differed at three amino acid positions, 
E114G V235A and L256F. All of these SNPs were located in the N terminal domain 
of the C. oncophora GluClα3 subunit, the ligand binding site area, although it is 
important to note the actual ivermectin/ moxidectin binding sites are still unknown 
(Njue et al. 2004), but are thought to be in the transmembrane regions due to the 
hydrophobic nature of the macrocyclic lactone drugs. 
The subunits carrying the candidate SNPs were cloned and expressed in Xenopus 
laevis oocytes. Electrophysiological whole-cell voltage-clamp recordings showed that 
the L256F mutation in the GluClα3 was the only one that caused a small but 
significant threefold loss of sensitivity to glutamate from an EC50 of 29.7± 4 μM to 
100.6 ± 0.21 μM. The efficacy of the macrocyclic lactones ivermectin and moxidectin 
were also significantly reduced with this mutation with the EC50 increasing from 0.5 ± 
0.12 in IVS worms to 1.2 ± 0.11 μM in channels carrying the L256F mutation. It is 
also important to note that the GluClα3 channels from the Ivermectin resistant 
population had EC50 comparable to those carrying the L256F mutation, 96.1 ± 4.4 μM 
for glutamate and 1.3 ± 0.11 μM for ivermectin/moxidectin (IVR) (Njue et al. 2004). 
Whether this mutation alone is enough to confer resistance of the nematodes to the 






Surprisingly few studies have actually examined the molecular nature of macrocyclic 
lactone action in organisms such as parasitic nematodes (Cheeseman et al. 2001; 
Forrester et al. 2002) for which these drugs have important economic implications. 
Therefore, our current research has focused on examining the relationship between 
IVM and potential parasite targets such as the GluCl.  
 
 
The initial objective of this project was to elucidate pharmacological data on the H. 
contortus GluClα3B subunit using site directed mutagenesis to create single point 
mutations in the cDNA that had been found in populations of IVM-resistant parasitic 
nematodes of two species C. oncophora and H. contortus, and to see if the 
mutations conferred a change in affinity of the subunit to with the natural agonist 
glutamate and the anthelmintic drug ivermectin using both two-voltage clamp 








4.2.1 Results of site directed mutagenesis   
 
 
The PCR product of the mutagenesis for all reactions was sequenced in an area 
localised to the mutation. Three of the mutations (E114G, V235A and L256F) were 
originally discovered as polymorphisms in Cooperia oncophora (Njue et al. 2004). 
L256F was discovered to confer loss of sensitivity in C. oncophora and in H. 
contortus so alternative aromatic amino acid substitutions at the same position were 
incorporated. The T300S mutation was discovered by our lab as a polymorphism 
between IVS and IVR H. contortus (Jagannathan 1998),  The V69E, S295T and 
T362A mutations were discovered as differences between in IVR and IVS H. 
contortus (Walsh et al, unpublished). Several mutations found in Drosophila 
melanogaster have been found to cause resistance to IVM. A mutation in the Dm 
GABAA (A302S) has been implicated in IVM resistance (ffrench-Constant et al. 1993; 
ffrench-Constant et al. 1993) and a mutation in the Dm GluClα (P299S) also causes 
a loss of sensitivity to IVM, glutamate  and nodulisporic acid (Kane et al. 2000). The 
equivalent mutations (A308S and P316S) were incorporated into H. contortus 























T300S ACA to TCA T to S Electrophysiology, Ligand binding 
E114G GAG to GGG E to G Electrophysiology, 
Ligand binding 
V235A GTT to GCT V to A Electrophysiology, Ligand binding 
L256F CTC to TTC L to F Electrophysiology, Ligand binding 
L256W CTC to TGG L to W Ligand binding 
L256V CTC to GTC L to V Ligand binding 
L256Y CTC to TAC L to Y Ligand binding 
V69E GTG to GAG V to E Ligand binding 
A308S GCA to TCA A  to S Ligand binding 
P316S CCA to TCA P  to S Ligand binding 
S295T TCT to ACT S  to T Ligand binding 
T362A ACG to GCG T to A Ligand binding 
 




Full length cDNAs encoding H. contortus ivermectin susceptible clones are kept as 
lab stocks. The mutations were successfully incorporated into the IVS cDNA and 
confirmed sequencing cDNA (see Figure 21). The mutations E114G and V235A are 
a result of transitional substitutions at the second codon position while mutations 
L256F and T300S are caused by substitution of the first codon position. All three 
mutations found in C. oncophora  are thought to be in the N-terminal extracellular 
domain of the GluCl receptor (Njue et al. 2004). As the longest extracellular domain 
of the subunit this part of the channel is implicated in ligand binding. The mutation 










                            
Figure 21: Chromatogram showing sequencing results after successful incorporation 
of a single base change for the mutation E114G.  
The point mutation is highlighted by the red R in the consensus box 
 
 





In an attempt to determine whether the SNP’s contributed to an altered response to 
glutamate, the SNPs found in populations of IVR C. oncophora, (Njue et al. 2004) 
and a SNP found in IVR H. contortus were incorporated into the H. contortus 
GluClα3B subunit cDNA and transcribed into cRNA. The mutants, each representing 
one mutation were expressed individually in Xenopus oocytes. The T300S mutant, 
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when expressed alone failed to respond to glutamate and when expressed with wt at 
a ratio of 1:1 the resultant channels elicit responses identical to those of the wt 
channels alone, indicating that the T300S mutants are either not expressing protein, 
or that a functional channel is failing to assemble. Of the mutants that did express 
E114G and V235A showed dose-response curves similar to the IVS wt receptor with 
EC50 values of 31.5 ± 3.2 and 26.2 ± 2.5 μM respectively.  Conversely the L256F 
mutation caused a significant (p>0.0001) 3.3 fold increase in the EC50 to 92.2 ± 3.5 
μM (See, Table 6). Unlike in the wild type channels the concentration at which the 
L256F reach a maximal inward current is increased from 300 μM to 1mM. For the 
L256F mutation there is also a significant (p=0.0016) decrease in the Hill coefficient 
from 1.89± 0.35 in the wild type to 1.09 ± 0.16 indicating a loss of cooperativity for 
glutamate binding. The E114G mutation also shows a slightly shallower standard 
curve with a corresponding reduction in Hill number to 1.48 ± 0.31, although this is 
not significantly different. The V235A mutation has a Hill number very similar to that 





mutant EC50 (μM) Hill Number Oocytes (n) 
IVS wt 27.6 ± 2.7 1.89 ± 0.35 7 
E114G 31.5 ± 3.2 1.48 ± 0.31 6 
V235A 26.2 ± 2.5 1.97 ± 0.35 6 
L256F 92.2 ± 3.5 1.09 ± 0.16 8 




Table 6. Summary of effects of glutamate on mutant GluClα3B homomeric 
channels.  



























Figure 22: Dose-response curves of wild type and mutant dose- response curves for 
glutamate. 
Glutamate dose-response curves for oocytes injected with wild type or Mutant H. contortus GluClα3B 
cRNA. Data were normalised to the maximum glutamate responses seen with each oocyte, and are 
shown as the standard error of the mean of seven oocytes for the wt, six oocytes each for E114G and 
V235A mutants and eight oocytes for the L256F mutant.  
 
4.2.3 Saturation analysis of [3H]-IVM binding to GluClα3B mutants 
at position 256 
 
 
Studies on [3H]-IVM binding to GluClα3B with the L256F SNP caused a significant 
change in Bmax and Kd to the IVS wt GluClα3B. The L256F mutant shows a 6.5 fold 
increase in Kd from 0.35 ± 0.10 nM for wt to 2.26 ± 0.78 nM (see Figure 23A and 
Table 7). The wt shows a Bmax of 0.83 ± 0.06 pmol/mg, which is increased to 1.41 ± 
0.33 pmol/mg, with the L256F substitution a 1.7 fold increase. Due to these 
interesting results further substitutions to the leucine at position 256 were carried out 
and analysed. The L256Y substitution has Bmax of 1.16 ± 0.20 pmol/mg and a Kd of 
1.84 ± 0.49 nM both significantly higher (p>0.0001) than the wt (Figure 23B and 
Table 7). This trend continues with the L256W mutation which shows a Bmax of 1.22 
± 0.21 pmol/mg and a Kd of 2.02 ± 0.52 nM (Figure 23C and Table 7). The L256V 
mutation does not show such a large difference to the wt with a Bmax of 0.93 ± 0.14 
pmol/mg and a Kd of 0.79 ± 0.24 nM but is still significant (p=0.0217) (Figure 23D 
and Table 7). 
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Figure 23: Saturation of COS-7 membrane preparations transiently expressing mutant 
GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. 
A) Saturation data for L256F mutant GluClα3B protein. 
B) Saturation data for L256Y mutant GluClα3B protein. 
C) Saturation data for L256W mutant GluClα3B protein. 
D) Saturation data for L256V mutant GluClα3B protein.  
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For each reaction 10μg of membrane protein was incubated with various concentrations of [3H]-
IVM for 2 hours at room temperature. Non specific binding was determined in the presence of 




4.2.4 Saturation analysis of [3H]-IVM binding to GluClα3B mutants. 
 
 
Specific high affinity [3H]-IVM binding was observed to membranes from GluClα3B 
transfected cells carrying single-amino acid substitutions were assessed. The two 
SNPs found in IVR C. oncophora E114G and V235A (Figure 27A and B) showed no 
significant change in either Bmax when compared to the wt indicating that these 
mutations have no effect on ivermectin binding with Bmax  values of 0.87 ± 0.06 and  
0.79 ± 0.07 pmol/mg respectively. The  Kd values are also similar to that of the wt 
channel with the E114G SNP having a Kd of 0.39 ± 0.07 nM and V235A 0.32 ± 
0.09nM (Table 7). The T300S mutation failed to produce a functional channel when 
expressed in Xenopus oocytes but is expressed and binds ivermectin when 
expressed in COS-7 cells with a Bmax of 1.01 ± 0.16 pmol/mg which is just ~ 18% 
higher than wt and Kd  0.76 ± 0.25 nM which is more than double that of wt. Another 
mutation V69E resulted in a very similar pharmacology to that of the T300S mutation 
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Figure 24: Saturation of COS-7 membrane preparations transiently expressing mutant 
GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. 
A) Saturation data for E114G mutant GluClα3B protein. 
B)    Saturation data for V235A mutant GluClα3B protein 
For each reaction 10μg of membrane protein was incubated with various concentrations of [3H]-
IVM for 2hours at room temperature. Non specific binding was determined in the presence of 10μM 
unlabelled ivermectin. 
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Figure 25: Saturation of COS-7 membrane preparations transiently expressing mutant 
GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. 
C)  Saturation data for T300S mutant GluClα3B protein. 
D)    Saturation data for V69E mutant GluClα3B protein 
For each reaction 10μg of membrane protein was incubated with various concentrations of [3H]-























































































Figure 26: Saturation of COS-7 membrane preparations transiently expressing mutant 
GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. 
E) Saturation data for A308S mutant GluClα3B protein. 
F)    Saturation data for P316S mutant GluClα3B protein 
For each reaction 10μg of membrane protein was incubated with various concentrations of [3H]-























































































Figure 27: Saturation of COS-7 membrane preparations transiently expressing mutant 
GluClα3B with [3H]-IVM.  Inset is the Scatchard plot for each mutation. 
G) Saturation data for S295T mutant GluClα3B protein 
H) Saturation data for T362A mutant GluClα3B protein 
For each reaction 10μg of membrane protein was incubated with various concentrations of [3H]-







mutation Bmax pmol/mg Kd nM  n (n of transfection reactions) 
wt 0.83 ± 0.06 0.35 ± 0.10 8 (4) 
L256F 1.41 ± 0.33 2.26 ± 0.78 8 (5) 
L256Y 1.16 ± 0.20 1.84 ± 0.49 6 (4) 
L256V 0.93 ± 0.14 0.79 ± 0.24 6 (6) 
L256W 1.39 ± 0.28 2.51 ± 0.70 6 (3) 
E114G 0.87 ± 0.06 0.39 ± 0.07 6 (3) 
V235A 0.79 ± 0.07 0.32 ± 0.09 6 (3) 
T300S 1.01 ± 0.16 0.76 ± 0.25 8 (5) 
V69E 1.06 ± 0.15 0.80 ± 0.24 6 (4) 
A308S 0.90 ± 0.05 0.41 ± 0.06 6 (4) 
P316S 0.79 ± 0.07 0.92 ± 0.16 6 (3) 
S295T 0.81 ± 0.05 0.30 ± 0.06 5 (2) 
T362A 0.92 ± 0.05 0.37 ± 0.07 5 (2) 
 
 
Table 7. Summary of Bmax and Kd from radioligand binding studies with [3H]-IVM 
Wt values are highlighted in green and mutations that elicit more than two-fold increase in 






Assessment of the mutations found in populations of ivermectin resistant Cooperia 
oncophora was essential to determine whether they conferred resistance. Studies 
carried out on the C. oncophora GluClα3 concluded that a 3 fold loss of sensitivity to 
glutamate and a 2.5 fold loss of sensitivity to IVM (Njue et al. 2004) and led us to 
investigate whether these mutations played a similar role in other parasite species 
such as H. contortus. The potential importance of these particular mutations was due 
to the fact that they had occurred in vivo, and therefore could potentially occur 
  102
naturally in closely related species. To determine whether all three mutations in the 
IVR GluCl α3B contribute to loss of glutamate and ivermectin sensitivity, each 
mutation was introduced alone into the IVS GluCl α3B using site-directed 
mutagenesis. From preliminary studies the responses of Mutation E114G and 
mutation V235A receptors were similar to those of the IVS GluCl α3B receptor with, 
suggesting that the mutations at these positions had no influence on ligand binding. 
There is little difference caused by the E114G and V235A mutations concerning the 
sensitivity of the channels to IVM with the mutations having very little effect of [3H]-
IVM binding. It is clear that these mutations have no obvious individual effect of the 
pharmacology of the channel. Although both mutations are found in the N-terminal 
domain of the GluCLα3B channel neither mutation is located in the glutamate 
binding pocket. In contrast, L256F mutant channels were less sensitive to glutamate 
with an ~ 3 fold  increase in EC50 to 92.2 ± 3.5 μM , which proved a similar loss of 
sensitivity in C. oncophora to the IVR GluCl α3 receptor responses (Njue et al. 
2004), suggesting that the L256F mutation accounted for the difference between IVS 
and IVR GluCl α3 channels in response to these two ligands. The Hill number for the 
L256F mutant is 1.09 ± 0.16 whereas the IVS channels it is 1.89 ± 0.35. This 
indicates a loss of cooperativity between ligand molecules binding to the channel. 
The effect of the mutations on the sensitivity of the GluCl α3B showed a decrease in 
sensitivity to glutamate with the L256F mutation there was a shift to the right. The 
maximal response for glutamate in IVS GluCl α3B channels is ~ 300 μM with 100 μM 
giving a 95% maximal response. With the L256F mutation the maximal response is 
increased, with 1 mM eliciting an average 20% higher response than 300 μM. This 
was not found in the parallel Cooperia study where the maximal response remained 
constant between mutations and IVS channels. This may be due to differences 
between experimental procedures or between the two nematode species.  
The ligand binding studies show a reduction in sensitivity to [3H]- IVM binding with a 
6.5 fold increase in Kd for L256F. This mutation, causing an amino acid change from 
a leucine to a larger amino acid like phenylalanine with an aromatic group could 
cause a conformational change that influences ligand binding. Alternatively, leucine 
may contribute directly to ligand binding, and the substitution to a different amino 
acid may have changed the tertiary structure of the ligand binding site. This 
prompted the creation of further substitutions with different amino acids at the 256 
position for ligand binding studies.  The alternative substitutions at the 256 position 
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all show significant differences in their Kd  to that of the wt, with L256V producing 
0.79 ± 0.24 nM, significantly less than the L256F Kd but higher than wt. This could be 
due to the nature of the amino acid substitution. All amino acids chosen to substitute 
with leucine were neutral. Valine is the smallest amino acid substituted and most 
similar in structure to leucine, valine does not carry aromatic an aromatic ring and is 
highly hydrophobic like leucine with a hydropathy number of 4.2 (Kyte et al. 1982). It 
is possible that the similarities between these amino acids explain the smaller 
difference in the resulting Kd and very similar Bmax. The tyrosine substitution (L256Y) 
caused a Kd of 1.84 ± 0.49 nM and tryptophan (L256W) 2.51 ± 0.70 nM. Both these 
substitutions and the original phenylalanine (L256F) cause the greatest change in 
Kd. and all contain aromatic rings the most reactive of which is tryptophan as it 
contains a non-carbon atom (nitrogen) in the aromatic ring system and is considered 
more reactive than phenylalanine but less than tyrosine (Betts et al. 2003). This is 
represented in the results with tryptophan substitution causing the largest (7- fold) 
increase in Kd followed by phenylalanine and then tyrosine. To further study the 
amino acid substitutions carried out in the N-terminal domain of the subunit, in silico 
modelling of this region were undertaken and will be described in chapter 4. 
From the data shown it is clear that the L256F mutation confers loss of sensitivity to 
glutamate and ivermectin in H. contortus as seen with Cooperia. Ivermectin studies 
were carried out using [3H]-IVM because experiments carried out on Xenopus 
oocytes have limited success; because ivermectin is irreversible it is difficult to obtain 
dose response curves using the same oocytes. The only way of doing this is to add 
ivermectin in increasing doses over one electrophysiological reading. This does not 
allow for the normal recovery time between doses, it has also been observed that all 
concentrations of ivermectin can cause an “all or nothing reaction” with the even low 
concentrations (~1nM) resulting in a fully open channel with the time taken to open 
the channel decreasing with increasing concentration. The C. oncphora study states 
that there is a three fold decrease in sensitivity to ivermectin with the L256F 
mutation. But with an n of 2 oocytes for the ivermectin studies for L256F mutation 
and an n of 3 for the IVS (Njue et al. 2004), the low n raises concerns over the 
statistical significance of this result especially due to the variable nature of 
electrophysiology with ivermectin (as previously discussed in chapter 3).  However, 
the work H. contortus L256F mutation complements the results in Cooperia which 
uses an n of 3. Electrophysiology with ivermectin is also made more difficult with the 
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fact that only one oocyte can be treated with ivermectin each day due to the nature 
of the drug. Ivermectin is hydrophobic and ‘sticky’ even in low concentrations (10nM) 
and remains stuck to the plasticware long after an application of the drug.  A 
separate perfusion system was used solely for ivermectin but it must be soaked in 
ethanol overnight to remove all traces of ivermectin between applications. As a 
result, it is easier and more reliable to conduct IVM studies using radiolabelled 
ligands at low concentrations avoiding the difficulties described above.  
   
The GluClα3B subunits carrying the T300S mutation did not respond to either 
glutamate or IVM. It was not known if the channel successfully assembled on the 
surface or if the mutation triggered a problem in the protein synthesis or assembly 
pathways. Successful expression in the COS-7 cells indicated that the problem was 
not in the synthesis of the protein subunit as the subunit bound IVM with high affinity. 
The ligand binding studies do not require the formation of functional channels on the 
surface of the cell like the electrophysiology experiments, rather, all that is necessary 
is any protein found in the membrane that has a functional IVM binding site. This 
may be suggestive of an assembly or trafficking problem as protein, stuck 
undergoing post translational modification in the endoplasmic reticulum or vesicles 
will also be collected in the membrane preparation. Alternatively, the problem may lie 
in the channel expression in Xenopus oocytes, the mutation may cause a problem in 
the endogenous Xenopus protein synthesis apparatus of the cell and it may be able 
to express a functional channel in another expression system. With the current 
information we have it is impossible to say what caused the lack of 
electrophysiological data.  The T300S mutation caused an increase in the Kd from 
0.35 ± 0.10 nM to over double this value at 0.76 ± 0.25 nM, However neither the  Kd 
or the Bmax for T300S are significantly different from wt (p=0.0585). I would not have 
expected a big change from wt in either electrophysiology or radioligand binding 
studies due to the very subtle substitution of threonine to serine which is effectively 
just the loss of a methyl group. Both amino acids are polar, neutral and have 
hydropathy index of -0.8 to -0.7 (Kyte et al. 1982) respectively showing them to be 
slightly hydrophobic which is common for amino acids found in transmembrane 
regions. The 2-fold increase in Kd may be due to the T300S mutation being involved 
in the IVM- binding domain, so even a subtle amino acid change may cause a 
noticeable effect on ligand binding.  The actual binding site of IVM is still unknown, 
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but from earlier competition studies it is known that IVM does not share a binding site 
with glutamate (Cheeseman et al. 2001), from the hydrophobic nature of the IVM 
molecule it can be hypothesised that the IVM would stay in the cell membrane and 
bind the channel on the transmembrane regions the TM2 region where the T300S 
mutation is found is inaccessible when the channel is closed but due to the twisting 
mechanism of channel opening would become available to proteins in the cell 
membrane when open (Hucho 1986; Celie et al. 2004). This makes the TM2 region a 
feasible participant in IVM binding, although this would suggest that glutamate or 
another agonist would need to be present for IVM action.  Due to the unknown 
nature of IVM binding, further study of the structure of GluCl channels needs to be 
undertaken and only when a clearer picture of the structure has been determined 
can experiments targeting the IVM binding sites be designed. The values elucidated 
for T300S mutation are very similar to those found for the V69E mutation despite this 
mutation being located in the N-terminal region of the subunit and not the membrane 
region like the T300S. V69E causes a 2-fold increase in Kd from wt at 0.35 ± 0.10 nM 
to 0.80 ± 0.24 nM in IVM despite being nowhere near the proposed IVM binding site. 
The substitution of valine to glutamic acid is a big change. With glutamic acid being 
polar, acidic and extremely hydrophilic where valine is nonpolar and neutral and also 
very hydrophobic (Betts et al. 2003). Further study was carried out to determine if the 
changes in these properties at the V69 position caused any conformational changes 
in the tertiary structure of the subunit that may explain this result (See chapter 4). 
 
The GluClα3B belongs to the same LGIC superfamily with with nicotinic 
acetylcholine receptors (nAChR), which are found in all organisms and are drug 
targets for insecticides known as the neonicotinoids, such as imidacloprid. The 
L256F mutation does not map onto any of the equivalent six domains of the nAChR 
subunits that form the acetylcholine binding site (Corringer et al. 1995; Corringer et 
al. 2000; Brejc et al. 2001) although alignment of these domains with the GluCl α3B 
is not totally clear. The fact that this mutation is not found in critical regions nAChR 
may explain the modest loss of agonist sensitivity observed (Njue et al. 2004). In 
Drosophilia melanogaster a single mutation in the M2-M3 linker region of Dm GluClα 
gene confers over 20-fold resistance to the novel insecticide, nodulisporic acid. 
Although the basis of the drug's insecticidal activity was not known, recent studies 
indicate that nodulisporic acid acts by a mechanism similar to that of ivermectin 
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(Kane et al. 2000; McHardy M. Smith et al. 2000) Electrophysiological studies of 
wild-type and mutant channels expressed in Xenopus oocytes revealed that 
nodulisporic acid directly activates Dm GluClα and that the mutation P299S renders 
the channel less sensitive to activation by nodulisporic acid, ivermectin, and the 
endogenous glutamate (Kane et al. 2000).  It has also been found mutation in the 
TM2 region of the rdl gene that codes for a GABA-gated channel confers high-level 
resistance to the insecticide dieldrin. This mutation not only identifies a single amino 
acid conferring high levels of resistance to the important GABA receptor antagonist 
picrotoxin (PTX) but also, by conferring resistance to cyclodienes (ffrench-Constant 
et al. 1993). These drosophila SNPs were also incorporated into the GluClα3B 
subunit to undergo radioligand binding analysis and the equivalent mutation in H. 
contortus was at the position P316S and resulted significant (p=0.0006) loss of 
sensitivity to IVM with a 2.6- fold increase in KD.   
 
In conclusion it has been shown that several single amino acid substitutions 
introduced into GluClα3B subunit have a significant effect on agonist affinity. In order 
to further characterise these pharmalogical effects, it is necessary to understand the 
position and importance of each amino acid that has been substituted. With current 
understanding of the secondary and tertiary structure of the GluCls, the amino acid 
positions can only be allocated into general areas. The next chapter focuses on 
trying to pinpoint the position of amino acids within the N-terminal domain and 
therefore to elicit a greater understanding of the importance of mutations such as 






Chapter 5: Analysis of the position of Single 
Amino Acid substitutions in the N-terminal 
region of the H. contortus GluClα3B subunit 












Our understanding of the structure of the ligand gated chloride channels is still far 
from complete, but great headway has been made in understanding the structure of 
the primary family member: the nicotinic acetylcholine receptor. Understanding this 
structure is essential for creating a template for understanding the conserved regions 
in all the ligand gated ion channels including ionotropic, glutamate and 5HT 
channels.  
Ligand gated ion channels are vastly important in several fields of research. They 
make up crucial parts of the excitory and inhibitory pathways in the central and 
peripheral nervous systems and implicated in mammalian diseases such as 
Alzheimer’s, Parkinson’s and epilepsy amongst many others. They are excellent 
drug targets for a whole range of drugs. Understanding how these incredible and 
highly important channels are built and organised will be helpful in targeting research 
more usefully and carefully. 
 
 
Although high-resolution crystal structures of other receptors or their domains have 
become commonplace, the ligand gated ion channel field has had to make do with 
low-resolution electron microscopy images of nAChR (Unwin 2005) (4 Å) or with the 
structure of a remote water-soluble homolog from Lymnea stagnalis (Brejc et al. 
2001). Last year a new  high-resolution crystal structure of the extracellular portion of 
the nAChR α1 subunit bound to α bungarotoxin at 1.94 Å resolution (Dellisanti et al. 
2007). This paper provides a significant breakthrough, putting existing data into 
perspective and supplies high-resolution insights (Sixma 2007). With channels that 
have membrane spanning domains it is extremely difficult to crystallize a single 
ligand binding domain of the nAChR in isolation. The nAChR ion channels have five 
homologous or identical subunits, with an extracellular domain that binds ligands at 
an aromatic site that lies at the interface of an α subunit and its neighbour (Sixma 
2007). Ligand binding triggers a gating signal in the transmembrane domain, which 
opens its gate for ions to pass through the channel pore. In all members of the 
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superfamily, the extracellular domain has a conserved loop of 13 amino acids that is 
flanked by a disulfide bridge. Therefore, the superfamily of pentameric ligand-gated 
ion channels, which also includes GluCls GABAA, 5HT3 serotonin and glycine 
receptors, is also known as the family of cys-loop receptors. Although the 
extracellular domains are separate units that can even be exchanged between 
receptors, it has been remarkably difficult to engineer soluble ligand-binding 
domains. (Sixma 2007) 
 
 In recent years advances in homology modelling have allowed scientists to create 
potential models of proteins based on similarities to existing data of known crystal 
structures. Previously this technique was the reserve of the few scientists with strong 
backgrounds in several programming languages such as Perl and modelica but the 
release and development of the Modeller program has allowed scientists to use a 
more user friendly method of molecular modelling (Sali et al. 1993), each new 
version that became available became easier to use. The Modeller 9 version 2 that 
came out in 2007 was the first that required little or no knowledge of programming 
and allowed non- computer experts to use it. This new user-friendly tool and the 
advances in nicotinic crystal structure analysis allowed us to attempt to create the 
first homology models  of GluClα3B subunits, although, at the present only the 
extracellular portion can be modelled as only crystal structures of the extracellular 
domains of nAChRs are available to use  as templates.  
 
The main objective of creating molecular models of the N-terminal domain of 
GluClα3B subunit is to understand the position and importance of the mutations of 
interest discussed in previous chapters.  
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5.2 Results 
All computations and simulations were carried out using a Sony vaio VGN-A397XP 
laptop computer running Microsoft windows XP professional. Modelling was only 
carried out on the N-terminal domain of the GluClα3B subunit. This is because 
known crystal structures have only been created using soluble proteins. The 
hydrophobic nature of the transmembrane regions make the creation of crystals and 
the subsequent X-ray experiments very difficult, therefore the decision was made to 
concentrate on the extracellular domain as this is the site of ligand binding.  
5.2.1 Selecting the template 
 
 
GluClα3B N-terminal amino acid sequence was compared, using BLAST, to those in 
the protein structure database (PDB). BLAST is a pair-wise sequence alignment 
program based on approximation of dynamic programming algorithms. The program 
looks for local alignments, short stretches of identical residues, in both the query and 
database sequences. A parallel comparison was also carried out using the modeller 
9v2 program.  
For the modeller GluClα3B query sequence the top alignments came out as 1i9BA-
E. These same resultant sequences of acetylcholine binding protein came out with 
the BLAST search; although not the top match, it was the best match over 50 amino 
acids long. As a result the acetylcholine binding protein subunit from Lymnea 
stagnalis was chosen as the template. Interestingly the majority of the remaining 50 
matches were alternative crystal structures of the acetylcholine binding protein as 
indicated from the similar E- values and other data shown in Figure 28. The Expect 
value (E) is a parameter that describes the number of hits one can "expect" to see by 
chance when searching a database of a particular size. It decreases exponentially as 
the Score (S) of the match increases. Essentially, the E value describes the random 
background noise. For example, an E value of 1 assigned to a hit can be interpreted 
as meaning that in a database of the current size one might expect to see 1 match 
with a similar score simply by chance. Consequently the E-value can be used to 
assess the level of confidence in the alignment, and the smaller it is, is due to 
homology rather than chance. The E-value  
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of 0.17x10-5, a very low number that proves that the sequence homology between 
the GluClα3B subunit and the 1i9B is very unlikely to be down to chance, and that 
the two structures are, in fact, similar  
 
Figure 28: Result of template search for GluClα3B- N-terminal region. 
The most important columns in the profile.build() output are the second, tenth, eleventh and twelfth 
columns. The second column reports the code of the PDB sequence that was compared with the target 
sequence. The PDB code in each line is the representative of a group of PDB sequences that share 
95% or more sequence identity to each other and have less than 30 residues or 30% sequence length 
difference. The eleventh column reports the percentage sequence identities between GluClα3B- N-
terminal region and a PDB sequence normalized by the lengths of the alignment (indicated in the tenth 
column). In general, a sequence identity value above approximately 25% indicates a potential template 
unless the alignment is short (i.e, less than 100 residues). A better measure of the significance of the 
alignment is given in the twelfth column by the e-value of the alignment.  
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5.2.2 Aligning the sequences 
 
 
Since the accuracy of the homology model is related to the degree of sequence 
identity and similarity between the template and target, particular attention was paid 
to the structural template selection and sequence alignment steps which are crucial 
in any homology modelling. The GluClα3B query was aligned using the modeller 
9v2. According to the values generated by the modeller program the sequence 
identity between the template and the query is 30% (See Figure 28). The minimum 
requirement for a potential template is 25% identity over more than 100 amino acids 
(Sali et al. 1993). 
 
Figure 29:  Modeller alignment of GluClα3B N-terminal domain 






In order to better understand the nature of the similarities between the proposed 
template and GluClα3B further study was carried out to determine structurally 
conserved and variable regions, the query sequences were annotated using the 
secondary structure of the template using ESPript 2.2. The Risler Matrix was used, 
which is derived from amino acid substitutions in aligned 3D structures rather than 
the commonly used PAM model which is designed to track the evolutionary origins of 
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proteins or the BLOSUM matrix, used to identify only conserved domains. The Risler 
Matrix also provides an added layer of refinement by in identifying amino acids of 
interest (Mount 2004). 
A multiple alignment of the IVS wt GluClα3B N-terminal region vs. the Lymnea 
stagnalis amino acid sequence was carried out using ClustalW and then the 
resultant file was uploaded to the ESPript 2.2 web-interface. The resultant alignment 
expands on the information showing not just identical residues but ones with similar 
properties. It is also useful to note that the areas that are more highly conserved are 
usually areas important to the secondary structure (Figure 29). The N-terminal 
regions of the GluClα3B subunits carrying mutations in this region were also studied 
to elucidate whether the mutations were carried in conserved regions where it would 
be easy to see if they have a conformational effect on the channel.  Of the mutations 
in the N-terminal region the V69E mutation is the only one in a conserved area on 
the first β-sheet.  
It is also worth noting that the extracellular portion of the GluClα3B subunit is 
significantly longer than that of the template at 263 amino acid residues in length 
compared to 205 in the template. The areas of extra sequence are found in one 
major area, the first N-terminal region prior to any conserved secondary structures, 
this is due to the presence of a signal peptide. There are also several stretches of 
extra residues between two and seven amino acids in length throughout the subunit 
(see Figure 31). These areas that don’t have a template will still be modeled using 




Figure 30: sequence alignment of acetylcholine binding protein (pdb 1I9B) and GluClα3B N-terminal domain. 
The secondary structure of the acetylcholine binding protein is shown above the alignment. Identical residues are shown as white letters on a red 
background and similar residues are shown as red on a white background. The βn represents β sheets, αn represent alpha helicies, TT shown above 
the residues indicates a sharp β-turn. The disulphide bridge caused by paired cysteine residues are illustrated with green numbers. The black dots 




Figure 31: sequence alignment of acetylcholine binding protein (pdb 1I9B) and Mutant 
GluClα3B N-terminal domain. 
The secondary structure of the acetylcholine binding protein is shown above the alignment. Identical 
residues are shown as white letters on a red background and similar residues are shown as red on a 
white background. The βn represents β sheets, αn represent alpha helices’, TT shown above the 
residues indicates a sharp β-turn. The disulphide bridge caused by paired cysteine residues are 
illustrated with green numbers. The black dots above the sequence are space markers every 10 
residues. Introduced SNPs are highlighted in green  
 
 5.2.3 Building and choosing the models 
 
Due to the relatively low homology to the template 50 models were built using 
Modeller 9v2 for each of the wt and mutant GluClα3B N-terminal subunits and the 
corresponding homomeric subunits. Each putative model was attributed a Modeller-
generated energy score known as the objective function (molpdf) which is essentially 
the sum of all the restraint functions and has no units. This score can be used to 
assess the energy of the protein model and the model returning the lowest energy 
score, for each target sequence, was selected as the best probable structure. 
 
5.2.4 Assessing the models 
 
Each of the potential models were assessed with Modeller 9v2 using the standard 
evaluate-model script. In addition to the propriety Modeller energy score, this is 
being minimised by the algorithm when building the model to satisfy spatial 
restraints, the script also generates a DOPE score, which has no units, that 
assesses the energy of the overall protein model . Although using different criteria, 
both scores are similar and should correlate, i.e. a good model will have a low 
energy score and a low DOPE value. An ideal model would have DOPE and energy 
scores similar to that of the template.  
All objective function and DOPE scores- as calculated by Modeller are listed in Table 
8. Due to the relatively low homology between the GluClα3B subunit and the 
acetylcholine binding protein some discrepancy was expected and in the case of the 
objective function this is the case with the template having a lower energy value 
compared to that of the GluClα3B subunit 5456.7 compared to >8000. This can be 
explained by the fact that the template sequence in significantly shorter than the 
query subunit and will have fewer restraint functions. The DOPE scores are 
considered to be a far better way of assessing the suitability of the model and in this 
case the scores are far more similar. The GluClα3B subunit, wt and mutant, show 
DOPE values lower then the template indicating that they are structurally more 










Name Objective Function(no units) 
DOPE Score 
(no units) 
1I9BA (template) 5456.7 -118049.9 
GluClα3B 8321.2 -120249.6 
L256F 8242.1 -122581.3 
L256Y 8759.3 -122218.0 
L256W 8519.1 -120885.8 
L256V 8299.4 -120672.7 
V235A 8483.8 -120598.3 
E114G 8315.6 -121138.8 
V69E 8557.2 -119848.9 
 
 
The final selected structure (Figure 32) shows a GluClα3B single asymmetric subunit 
consisting of an N-terminal α-helix, two shorter 310 helices, which are arranged in a 
typical right-handed helical structure with each amino acid, corresponds to a 120° 
turn in the helices, and a core of 10 major β- strands, forming a β sandwich. The 
order of the β assembly conforms to the modified immunoglobin (Ig) topology noted 
in the nAChRs (Copley et al. 1994). There is also a short length of a β strand found 
prior to the β-sandwich structure known as β1 on Figure 31.  
In the structure, the N and C termini are located at 'top' and 'bottom' of the pentamer, 
respectively. In the ion channels the transmembrane domains are at the C-terminal 
end of the LBD, at the 'bottom' of the GluClα3B structure, starting directly at the end 
of β-strands 10 and 11. 
The pentameric structure fits together in a energetically favourable manner and 
shows the characteristic “petal like” conformation when viewed along the five–folds 





Figure 32: Model of the final wt GluClα3B models 
A) Side view of a cartoon model of a single GluClα3B subunit. Rainbow colours illustrate the 
progression from the N-terminus (blue) to the C-terminus (red).  
B) Top and side views of cartoon model of the pentameric structure of the wt channel. Each subunit is 





 5.2.5 Model of GluClα3B V69E mutant. 
 
 
Amino acid 69 is a region of the GluClα3B channel that is conserved with the AChBP 
template (see Figure 31).  Molecular modeling of the subunit shows that this residue 
interacts with amino acids at positions 67, 70, 96, 97, 98, 208 and 209 (see Table 9 
and Figure 31). Position 69 is found in the core of the β-sandwich and as a result is 
not involved in any subunit-subunit interactions (Figure 33A and Figure 32).  
The valine at position 69 in the wt channel is the first amino acid of the first β-strand, 
the substitution of valine to glutamic acid results in a loss of participation in the β-
strand.  Valine is hydrophobic, and prefers to be buried in protein hydrophobic cores. 
However, like isoleucine, and threonine it is C-β branched. Whereas most amino 
acids contain only one non-hydrogen substituent attached to their C-β carbon, these 
three amino acids contain two resulting in a higher density of molecular structures 
close to the protein backbone, meaning these amino acids are more restricted in the 
conformations the main-chain can adopt. Perhaps the most pronounced effect of this 
is that it is more difficult for these amino acids to adopt an alpha-helical 
conformation, though it is easy and even preferred for them to lie within beta-sheets 
(Betts et al. 2003). Glutamic acid is larger and negatively charged and polar, 
therefore more likely to be found on the outside edge of the extracellular domain, it is 
also more flexible in the backbone area resulting in the shortening of the first β-
stand. 
From  the ball and stick part of Figure 34 we can see that in the V69 model the valine 
primarily interacts with E96, but following the V69E substitution the two negatively 








   
Figure 33: Model representation of the pentameric homomer of the V69E 
GluClα3B subunit. 
The structure is shown as a cartoon representation with each subunit a different colour. The Glutamic 
acid at position 69 is shown as a spacefill molecule. 
                           
 
Position Residue Representative colour 
69 Valine/Glutamic acid Natural grey 
68 Leucine Blue 
70 Threonine Light Blue 
208 Tyrosine Light orange 
209 Glutamic acid Orange 
96 Glutamic acid Pink 
97 Glutamic acid Purple 
98 Tryptophan Red 
 
 
Table 9. Table summarising the amino acids in contact with V69E in the 
GluClα3B subunit. 




Figure 34: Model of the GluClα3B N-terminus carrying the V69E mutation 
A) Cartoon model of the side view of a single GluClα3B subunit. Inset cartoon of model carrying the 
V69E mutation. The blue box represents the areas enlarged in 7B)  
B) Cartoon model of the pentameric structure of the wt channel with ball and stick (top) and spacefill 
(bottom) illustrations of the residues including and contacting position 69. The pictures on the left are of 
a Valine at residue 69 and the pictures of the right are of a glutamic acid at position 69.  
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Residue 114 is found in an area of the subunit that has no direct conservation with 
the template, but is in the middle of an otherwise conserved area.  It has a limited 
range of interactions, but according to the model interacts primarily with the proline 
at position 6.It is also relatively close to the edge of the subunit but is too high to be 
involved in subunit-subunit interactions. 
Glutamic acid is a negatively charged, polar amino acid. Being charged and polar, 
glutamatic acid generally prefers to be on the surface of proteins, exposed to an 
aqueous environment. (Betts et al. 2003).  Any interaction between E114 and P6 is 
lost when the E114G substitution takes place. Glycine is a unique amino acid in that 
in contains hydrogen as its side chain (rather than a carbon as is the case in all other 
amino acids). This means that there is much more conformational flexibility in 
glycine. What this means is that glycine can reside in parts of protein structures that 
are forbidden to all other amino acids (e.g. tight turns in structures). In the case of 
this mutation it is the fact that glycine is much smaller than glutamic acid that causes 
change. From Figure 36 we can see that the original amino acid meets the P6, but 








Figure 35: Model representation of the pentameric homomer of the E114G 
GluClα3B subunit. 
The structure is shown as a cartoon representation with each subunit a different colour. The glycine at 







Table 10. Table summarising the amino acids in contact with E114G in the 
GluClα3B subunit. 
 The table also describes the colour of the residues illustrated in Figure 34 
 
Position Residue Representative colour 
114 Glutamic acid/ Glycine Natural grey 
113 Threonine purple 
115 Valine Light purple 
6 Proline Green 




Figure 36: Model of the GluClα3B N-terminus carrying the E114G mutation 
A) Cartoon model of the side view of a single GluClα3B subunit. Inset cartoon of model carrying the 
E114G mutation. The blue box represents the areas enlarged in 8B)  
B) Cartoon model of the pentameric structure of the wt channel with ball and stick (top) and spacefill 
(bottom) illustrations of the residues including and contacting position 114. The pictures on the left are 
of a glutamic acid at residue 114 and the pictures of the right are of a glycine at position 114.  
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5.2.7 Model of GluClα3B V235A mutant. 
 
 
Position 235 is found at the bottom of the β-sandwich in a highly conserved area of 
β10 the ninth β-strand of the sandwich. On the pentameric structure it is found on the 
outside facing edge and interacts primarily with residues on the final β11 strand. The 
most important of these residues is L256. The substitution of a valine to an alanine is 
a relatively minor substitution, whereas valine is hydrophobic and aliphatic its 
position at the heart of a β-strand indicates a more structural purpose and the 
substitution to alanine which is not particularly hydrophobic though neither is it polar. 
From the model pictures we can see there is little or no effect of the substitution on 










Position Residue Representative colour 
235 Valine / Alanine Natural grey 
234 Valine Light blue  
236 Threonine  Blue  
254 Lysine  Pink  
255 Leucine  Purple 
256 Leucine Red 
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Figure 37: Model representation of the pentameric homomer of the V235A 
GluClα3B subunit. 
The structure is shown as a cartoon representation with each subunit a different colour. The alanine at 
position 235 is shown as a spacefill molecule 
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Figure 38: Model of the GluClα3B N-terminus carrying the V235A mutation 
A) Cartoon model of a single GluClα3B subunit. Inset cartoon of model carrying the V235A mutation. 
The blue box represents the areas enlarged in 9B). Yellow arrows point to the position of the disulphide 
bridge.  
B) Cartoon model of the pentameric structure of the wt channel with ball and stick (top) and spacefill 
(bottom) illustrations of the residues including and contacting position 235. The pictures on the left are 
of a valine at residue 235 and the pictures of the right are of an alanine at position 235.  
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The leucine at position 256 is adjacent to a relatively large number of amino acids 
and in the pentameric structure is found in the centre of the outside face of the 
channel.  The two residues that are most closely in association with the Leucine 256 
are V235 and L193. In the wt channel the leucine appears to be neither attracted nor 
repulsed by any of its neighbours, which is understandable as they are all relatively 
un-reactive side-chains. Being hydrophobic, leucine prefers to be buried in protein 
hydrophobic cores. It also shows a preference for being within α-helices more so 
than in β-strands (Betts et al. 2003), neither of which condition is present in the wt 
strand.  
The modelling of the substitution of leucine to phenylalanine results in an obvious 
interaction with the neighbouring polar amino acid asparagine at residue 191 in 
which an attraction seems to be occurring (see Figure 40). This phenomenon is also 
seen with the L256V and L245Y mutations (see Figure 41 and Figure 42), strangely 
the L256W has no apparent effect on the N191 residue.  
Phenylalanine, tryptophan and tyrosine are all aromatic and hydrophobic whereas 
valine is not aromatic but is still hydrophobic.   
The L256V mutation causes attraction of N191 and also a resulting change in 
orientation of the polar K254 residue, which is also seen in all the L256 mutants. 
There is no change in any interaction with the V235 residue, with the exception of a 











Table 12. Table summarising the amino acids in contact with L256 in the 
GluClα3B subunit 
 
Position Residue Representative colour 
256 Leucine/ mutant Natural grey 
254 Lysine Pink 
255 Leucine Purple 
257 Leucine Red 
235 Valine Cyan 
234 Valine Light blue 
236 Threonine Blue 
191 Asparagine Green 
192 Cysteine Yellow 
193 Leucine Orange 
 
 
Figure 39: Model representation of the pentameric homomer of the L256 
mutant GluClα3B subunits. 
The structure is shown as a cartoon representation with each subunit a different colour. The residues at 




Figure 40: Model of the GluClα3B N-terminus carrying the L256F mutation 
A) Cartoon model of the side view of a single GluClα3B subunit. Inset cartoon of model carrying the 
L256F mutation. The blue box represents the areas enlarged in 10B) Yellow arrows point to the position 
of the disulphide bridge 
B) Cartoon model of the pentameric structure of the wt channel with ball and stick (top) and spacefill 
(bottom) illustrations of the residues including and contacting position 256. The pictures on the left are 
of a leucine acid at residue 256 and the pictures of the right are of a phenylalanine at position 256.  
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Figure 41: Model of the GluClα3B N-terminus carrying the L256Y mutation 
A) Cartoon model of the side view of a single GluClα3B subunit. Inset cartoon of model carrying the 
L256Y mutation. The blue box represents the areas enlarged in 11B) Yellow arrows point to the position 
of the disulphide bridge 
B) Cartoon model of the pentameric structure of the wt channel with ball and stick (top) and spacefill 
(bottom) illustrations of the residues including and contacting position 256. The pictures on the left are 
of a leucine acid at residue 256 and the pictures of the right are of a tyrosine at position 256.  
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Figure 42: Model of the GluClα3B N-terminus carrying the L256V mutation 
A) Cartoon model of the side view of a single GluClα3B subunit. Inset cartoon of model carrying the 
L256V mutation. The blue box represents the areas enlarged in 12B) Yellow arrows point to the position 
of the disulphide bridge 
B) Cartoon model of the pentameric structure of the wt channel with ball and stick (top) and spacefill 
(bottom) illustrations of the residues including and contacting position 256. The pictures on the left are 
of a leucine acid at residue 256 and the pictures of the right are of a valine at position 256.  
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Figure 43: Model of the GluClα3B N-terminus carrying the L256W mutation 
A) Cartoon model of the side view of a single GluClα3B subunit. Inset cartoon of model carrying the 
L256V mutation. The blue box represents the areas enlarged in 13B) Yellow arrows point to the position 
of the disulphide bridge 
B) Cartoon model of the pentameric structure of the wt channel with ball and stick (top) and spacefill 
(bottom) illustrations of the residues including and contacting position 256. The pictures on the left are 
of a leucine acid at residue 256 and the pictures of the right are of a tryptophan at position 256.  
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5.3 Discussion  
 
Comparative modeling is based on the observation that in protein families, structure 
is more conserved than sequence (Russell et al. 1997). Consequently, the unknown 
structure of a protein can be approximated “by comparison” to the known structure of 
another member of the “fold” family (Ernst et al. 2003). 
The models created in this chapter can only be as accurate as their template allows 
them to be, and despite the production of higher resolution nAChR channels being 
published the highest alignment match against the GluClα3B subunit was the 
Acetylcholine-binding protein (AChBP), a soluble protein found in the snail Lymnaea 
stagnalis (Smit et al. 2001). It is produced and stored in glial cells, and released in an 
acetylcholine-dependent manner into the synaptic cleft, where it modulates synaptic 
transmission. A mature AChBP is 205- 210 residues long and forms a stable 
homopentamer. It aligns well, the GluClα3B subunit but also with the N-terminal 
domains of pentameric LGICs and lacks the transmembrane and intracellular 
domains present in the superfamily (Smit et al. 2001). Of all the LGIC AChBP is, 
understandably,  most closely related to the α-subunits of the nAChRs (Brejc et al. 
2001), which are more similar in length and have a considerably higher level of 
homology than that of the GluCls or any other LGIC. The AChBP structure, thus, in 
principle is a valid template and presently the only one available for modeling all 
other superfamily members, especially due to the fact that the newer crystal 
structures have a higher resolution they also have ACh bound to them (Ernst et al. 
2003).  It is very difficult to say how accurate models are when they have such a low 
level of homology to the template, just 17% identity between GluClα3B and the 
AChBP at first glance, although this increases to 30% when you discount the extra 
60 amino acids present in the H. contortus sequence. Even mapping nAChRs onto 
the AChBP has its difficulties with homology, there have also been problems with 
modelling GABA receptors. In the GABAA receptor subunits there is an estimated 
60–75% of amino acid residues possess structural equivalents in the modeling 
template AChBP, and like the GluClα3B most variation is found at beginnings and 
ends of the secondary structure motifs, through the lengths and conformations of 
loops, and in number, placement and length of shorter β-strands and helices (Brejc 
et al. 2001; Ernst et al. 2003). Therefore lengths of residues within secondary 
structures are more reliably modeled, than those at the ends. 
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Apart from the alignment issues, which can be overcome with careful manual 
observation of the alignment, some areas of the AChBP structure are probably 
anomalous within the LGIC family. For instance, L2 as well as L7 (the “cys-loop”) are 
located at the “bottom” (solvent exposed) surface in AChBP. In the receptors these 
regions are associated with the trans-membrane domain (Kash et al. 2003) and 
possibly with the membrane, certainly not exclusively with the aqueous surroundings 
as in AChBP. In these segments the AChBP structure thus is not an ideal template, 
which also is reflected by the lack of sequence conservation in L7 area (Brejc et al. 
2001). The C-terminus of the AChBP corresponds to the C-terminal end of the 
receptor extracellular domain. It has been shown recently that comparative models 
of the extracellular domain can be combined with models of the transmembrane 
domain without difficulties (Trudell 2002; Kash et al. 2003). Thus, the C-end of the 
comparative models appears to be reliable (Ernst et al. 2003). Therefore it was 
important to ensure that all mutations carried out in the modeling experiment were 
carried in areas of not only reasonably high homology, but in areas that correspond 
to the secondary structure.  All of the mutations investigated correspond to areas 
within β-strands, with mutations at position 69, 235 and 256 within the β sandwich 
and therefore supported by interactions between β-strands. Confidence is especially 
high in the information gathered from mutations in the C-terminal area such as those 
found at position 235 and 256.   
The models generated of the GluClα3B subunit show a sensible level of visual 
similarity to the template and also to the other known LGIC structures (see Figure 
43). Moreover the mathematical assessments carried out indicate that the protein 
folded in an energetically favourable way. The fact that the DOPE scores for the 
pentameric models are lower for the models gives a great deal of confidence to the 
final product. There are areas of the models that should not be fully trusted. As 
previously mentioned the GluClα3B subunit is 60 amino acids longer than the 
template resulting in areas of no homology. Although these areas have been folded 
mathematically, they still appeared less structured than the rest, as in evidence in all 
the pentameric figures. This area is obviously folded slightly differently in each 
subunit, and therefore should be dismissed as an area of study in modelling until a 





Figure 44: Diagram of nAChR subunit at 4 Å 
 
Ribbon diagrams of a single subunit, viewed parallel with the membrane plane, in orientations such that 
the central axis of the pentamer (vertical line) is (a) at the back and (b) to the side. The α-helices are in 
yellow; the β-strands composing the β-sandwich are in blue (inner) and red (outer). Locations of the N 
and C termini, Trp149, V46, the Cys-loop disulphide bridge and the membrane (horizontal bars) are 




Homology modelling of the GluClα3B mutants has proven interesting and useful. Of 
the mutants modelled, it was interesting to see that the L256F mutant and the V235A 
which were both observed, together in the same population of Ivermectin resistant  
Cooperia oncophora (Njue et al. 2004), are actually in close contact in situ.  The 
L256F mutation is responsible for a three fold loss of sensitivity to glutamate in 
functional channels and a 6.5 fold decrease in sensitivity to IVM, and although the 
V235A mutation apparently had no effect alone on either response to glutamate or 
IVM, it may have an effect when both mutations are expressed together. It raises the 
question of what caused these mutations in vivo, although both mutations and 
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indeed, the E114G mutation that was also observed in the IVR C. oncophora were 
all due to single base mutations, and therefore it is reasonable to assume the 
probability of mutation is quite high, but the probability that two substitutions 
occurred in the sequence, that produced two amino acid substitutions that directly 
interact with one another is lower, but still well within the realms of possibility.  
The mutations at position 256 illustrate the greatest conformational changes seen by 
any of the mutants. The L256 holds an important position within the structure of the 
β-sandwich. This position carries many neighbours including V235 as already 
discussed; it is also adjacent to C192 which holds one half of the disulphide bridge, 
one of the major structural properties of the ligand binding domain.  Substitution of 
L256 to phenylalanine and tryptophan cause the greatest pharmacological changes 
of the channel, demonstrating a 6 fold decrease in sensitivity to IVM (and a 3-fold 
loss to glutamate in the case of L256F), this is not seen with the valine substitution 
and to a lesser extent with tyrosine.  From observing the models there is no obvious 
reason for this, no strong interaction not present with valine or tyrosine. However it is 
clear to see that the larger the amino acid side chain the more sensitivity is lost, 
therefore it is reasonable to assume that steric hindrance may be to blame for 
altering the adjacent N191 and C192 residues and therefore altering the disulphide 
bridge. Although the 256 mutation is in an ideal area of the subunit for study i.e close 
to the reliable C-end of the extracellular domain, within secondary structure with 
close proximity to a disulphide bridge, we cannot rely of the modelling for showing 
individual atomic interactions, the template itself is only at a resolution of 2.7Å.  
Therefore in reality the small amino acid interactions may be inaccurate, but we can 
be confident of the positioning of the residues within the structure.  
The V69E mutation which carries a change from a C-β branched, neutral, 
hydrophobic amino acid to a negatively charged polar molecule results in a loss of 
the start of the β2 which is the first β-strand of the β-sandwich. The change in 
mutation doesn’t appear to have a significant change on the position of any 
surrounding residues but as previously discussed this may not be the case, but a 
genuine change is seen in in vitro experiments with the Kd of GluClα3B to IVM is 
more than doubled from 0.35 ± 0.10 nM to 0.8 ± 0.24 nM with the V69E substitution, 
this is not a big change, but it is possible that the loss of structural integrity of caused 
by the shortening of the β2-strand is enough to create a small effect on the binding 













The aim of this research was to assess and characterize the pharmacology of the H. 
contortus GluClα3B subunit and investigate the effects of specific single amino acid 
substitutions on subunit pharmacology in respect to glutamate, the natural agonist, 
and the anthelmintic drug ivermectin. Prior to this study it was known that GluClα3B 
formed homomeric channels that responded to glutamate and IVM. It was also 
known that different mutations in the glutamate gated chloride channels of other 
nematode and insect species conferred a level of resistance to IVM. This study 
introduced these mutations and others into H. contortus GluClα3B cDNA which was 
expressed either in Xenopus oocytes for electrophysiological readings or COS-7 
cells for ligand binding studies. The N-terminal domain of the GluClα3B was 
visualized by homology modeling using the related acetylcholine binding protein as a 
template in order to characterize the mutations and their effects on the channel 
further. 
One mutation found in IVR C. oncophora L256F confers a 3-fold loss of sensitivity to 
glutamate and a 6.5 fold loss of sensitivity to IVM.  This mutation is found in the C-
terminal area of the extracellular region of the channel and, from homology 
modeling, we know it lies in close proximity and possibly interferes with another 
candidate mutation V235A, and the cysteine residue at position 192 which forms one 
side of the structurally significant disulphide bridge. Further introduction of different 
mutations at this position showed the larger the substituted amino acid, the greater 
the effect on IVM sensitivity, indicating that the effect of the mutation is caused by 
steric hindrance pushing the surrounding amino acids apart, including the C192 thus 
mediating the effect on channel activity. There is currently no available data to know 
whether this loss of sensitivity is sufficient to cause IVM resistance in vivo.  
Another amino acid substitution (T300S) results in the prohibition of a functional 
channel in Xenopus oocytes, the reason for this currently unknown although it has 
been shown that the protein when produced in mammalian COS-7 cells is able to 
bind IVM with high affinity. 
Although significant progress has been made in understanding the effects of the 
mutants illustrated here, no mutant that has been investigated causes complete IVM 
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resistance, therefore no significant answer to the problem of IVM resistance has 
been forthcoming.  It appears that the cause of IVM resistance is not going to be as 
simple as in the case of BZ resistance, but screening of candidate mutations should, 
ideally, continue. Screening between IVS and IVR strains in the GluCl subunits of 
various nematodes such as D. immitis, A. suum and further study of H. contortus will, 
hopefully, unearth more polymorphisms that can be investigated and found to confer 
resistance. The creation of a homology model of the N-terminal region of the 
GluClα3B will allow a more targeted approach to designing mutations that may have 
an effect on ligand binding. 
It is increasing likely that the cause of IVM resistance is multigenic. A combination of 
several factors such as reduced ivermectin sensitivity (like L256F) with actions by P-
glycoproteins and other factors may be enough to confer resistance. Some P-
glycoproteins and multidrug resistance proteins have been found to act as 
membrane transporters which pump drugs from the cell. It has been suggested that 
a disruption of the mdrla gene, which encodes a P-glycoprotein in mice, results in 
hypersensitivity to ivermectin. Some of the genes encoding members of the P-
glycoprotein family are known to exist in nematodes. Some data suggests that a P-
glycoprotein may play a role in ivermectin resistance in H. contortus (Xu et al. 1998). 
It is clear that in C. elegans the ML have multiple GluCl targets and so high level 
resistance requires mutations in multiple genes. This may explain why the 
avermectins have been relatively long lived effective antiparasitic drugs as a single 
mutation in one of the targets is not enough to confer resistance (Dent et al. 1997; 
Martin et al. 1998). However, there are some questions concerning the applicability 
of these very elegant C. elegans studies to parasitic species. It is unlikely that a 
reduction in ML sensitivity of > 4000 fold is necessary to cause clinical resistance 
and it may be that further studies on lower level resistance might yield better clues to 
its mechanism in parasites. Many of the C. elegans mutants are null, or functional 
nulls, and this complete loss of channel function has marked behavioral and other 
effects (Dent et al. 2000; Cook et al. 2006) that might make them too deleterious to 
allow parasites to survive in the wild. It is also interesting that the C. elegans screens 
have not identified a role for the P-glycoproteins (P-gp) in ML resistance, despite the 
evidence from parasites (Kerboeuf et al. 2003; von Samson-Himmelstjerna et al. 
2005). 
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Understanding the molecular pharmacology of the GluCl is highly important because 
the GluCls are only found in invertebrates and therefore make an ideal broad 
spectrum drug target for insecticides and endectocides. An in-depth knowledge of 
how the channels function is essential for not only tracking and understanding 
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7.1 Appendix 1. Map of vector pcDNA3.1 
 
 















T300S ACA to TCA F-5’ TCTCTGGGTGTCACGTCACTGCTCACAATGAC-3’ R-5’ GTCATTGTGAGCAGTGACGTGACACCCAGAGA-3’ 
E114G GAG to GGG F-5’ CGAATCCACGGGGGTGCCGCCGTT-3’ 
R-5’ AACGGCACCCCCGTGGATTCG-3’ 
V235A GTT to GCT F-5’ CGAATTCGAAGATGTCGCCACCAAGTACTGCACC-3’ R-5’ GGTGCAGTACTTGGTGGCGACATCTTGCCATTCG-3’ 
L256F CTC to TTC F-5’ GCTCGGGTCAAACTTTTCTTGCGAAGAGAGTACA-3’ R-5’ TGTACTCTCTTCGCAAGAAAAGTTTGACCCGAGC-3’ 
L256W CTC to TGG F-5' GTGCTCGGGTCAAACTTTGGTTGCGAAGAGAGTACAG 3' 
R-5' CTGTACTCTCTTCGCAACCAAAGTTTGACCCGAGCAC 3' 
L256V CTC to GTC F-5' CTCTCTTCGCAAGACAAGTTTGACCCGAG 3' 
R-5' CTCGGGTCAAACTTGTCTTGCGAAGAGAG 3' 
L256Y CTC to TAC F-5' GTGCTCGGGTCAAACTTTACTTGCGAAGAGAGTAC 3' 
R-5' GTACTCTCTTCGCAAGTAAAGTTTGACCCGAGCAC 3' 
V69E GTG to GAG F-5’ GGTCCTGTGCTGGAGACGGTAAACATC 3' R-5’ GATGTTTACCGTCTCCAGCACAGGACC 3' 
A308S GCA to TCA F-5’ GCTCACAATGACAACTCAGTCAAGCGGTATCAACTCC 3’ R-5' GGAGTTGATACCGCTTGACTGAGTTGTCATTGTGAGC 3' 
P316S CCA to TCA F-5' GTATCAACTCCAAACTCTCACCTGTCTCTTACATC 3' R-5' GATGTAAGAGACAGGTGAGAGTTTGGAGTTGATAC 3 
S295T TCT to ACT F-5’ CCAGCTCGAGTGACTCTGGGTGTCACG 3’ R-5’ CGTGACACCCAGAGTCACTCGAGCTGG 3’ 
T362A ACG to GCG F-5’ GGAGAAAAAGAAGAAACGCGTCTGGACGACTG 3’ R-5' CAGTCGTCCAGACGCGTTTCTTCTTTTTCTCC  3 
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7.3 Appendix 3. Modeller 9v2- procedure and scripts 
 
 
Example: Modelling of GluClα3B using 1I9B.pdb as a template  
 
GluClα3B amino acid sequence must be put in PIR format file, with the extension .ali 
it must be in a plain text format.  
 
All modeller command files are written in python programming language and carry 






Aligning the query and template sequences using the following ‘align2d.py’ 





The alignment will be written out in two formats, PIR and PAP. The PIR format is 
used in subsequent model building stages, while the PAP file is easy to examine and 
inspect visually.  
 
Once a target template alignment is constructed, MODELLER calculates a 3D model 







GLRQSLPSFELQDVVTKYCTSKTNTGEYSCARVKLLLRREYSY*   
 
from modeller import * 
 
env = environ() 
aln = alignment(env) 
mdl = model(env, file='1I9B', model_segment=('FIRST:A','LAST:A')) 







will generate a number of models based on the template and the alignment in file 







The highlighted areas can be changed depending on the query, template and the 
required number of models generated 
 
 
The output files from the “model-single.py” command are 
 ‘model-single.log’ which reports warnings, errors and other useful information 
including input restraints and preliminary DOPE  and objective function 
scores. 
 ‘GluCla3B. B000000x.pdb’ files which are the models generated by the 
program. Pdb files can be viewed with many different programs including 
raswin and chime.  
 
 
Once a final model has been selected based on its objective function and DOPE 
scores it can be evaluated a second time using the ‘evaluate-model.py’ command. It 
is also a good idea to evaluate the template and compare the results directly using 














from modeller import * 
from modeller.automodel import * 
 
env = environ() 
a = automodel(env, alnfile='GluCla3B-1I9BA.ali', 
              knowns='1I9BA', sequence='GluCla3B') 
     assess_methods=(assess.DOPE, assess.GA341))  
a.starting_model = 1 











Highlighted words can be changed for different pdb files that require evaluation 
The output files are carry the .profile extension and report DOPE and objective 
function scores a reasonable model will have similar values to the  template 
from modeller import * 
from modeller.scripts import complete_pdb 
 
log.verbose()    # request verbose output 
env = environ() 
env.libs.topology.read(file='$(LIB)/top_heav.lib') # read topology 
env.libs.parameters.read(file='$(LIB)/par.lib') # read parameters 
 
# read model file 
mdl = complete_pdb(env, '1I9BA.pdb') 
 
# Assess with DOPE: 
s = selection(mdl)   # all atom selection 
s.assess_dope(output='ENERGY_PROFILE NO_REPORT', file='1I9B.profile', 
              normalize_profile=True, smoothing_window=15) 
 
 
from modeller import * 
from modeller.scripts import complete_pdb 
 
log.verbose()    # request verbose output 
env = environ() 
env.libs.topology.read(file='$(LIB)/top_heav.lib') # read topology 
env.libs.parameters.read(file='$(LIB)/par.lib') # read parameters 
 
# read model file 
mdl = complete_pdb(env, 'GluCla3B.B000023.pdb') 
 
# Assess with DOPE: 
s = selection(mdl)   # all atom selection 
s.assess_dope(output='ENERGY_PROFILE NO_REPORT', file='GluCla3B.profile', 
              normalize_profile=True, smoothing_window=15) 
 
